WO2022095801A1 - Lir1-targeted antibody and use thereof - Google Patents
Lir1-targeted antibody and use thereof Download PDFInfo
- Publication number
- WO2022095801A1 WO2022095801A1 PCT/CN2021/127564 CN2021127564W WO2022095801A1 WO 2022095801 A1 WO2022095801 A1 WO 2022095801A1 CN 2021127564 W CN2021127564 W CN 2021127564W WO 2022095801 A1 WO2022095801 A1 WO 2022095801A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- seq
- cells
- lir1
- cdr
- Prior art date
Links
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 claims abstract description 84
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 claims abstract description 83
- 108700010039 chimeric receptor Proteins 0.000 claims abstract description 49
- 230000014509 gene expression Effects 0.000 claims abstract description 33
- 229940127121 immunoconjugate Drugs 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 66
- 210000002865 immune cell Anatomy 0.000 claims description 49
- 150000007523 nucleic acids Chemical class 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 108020004707 nucleic acids Proteins 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 36
- -1 NKG2B Proteins 0.000 claims description 34
- 239000003446 ligand Substances 0.000 claims description 32
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 230000002401 inhibitory effect Effects 0.000 claims description 30
- 239000013598 vector Substances 0.000 claims description 30
- 230000011664 signaling Effects 0.000 claims description 25
- 230000000139 costimulatory effect Effects 0.000 claims description 22
- 230000008685 targeting Effects 0.000 claims description 19
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 17
- 101000990055 Homo sapiens CMRF35-like molecule 1 Proteins 0.000 claims description 17
- 101000901669 Homo sapiens CMRF35-like molecule 8 Proteins 0.000 claims description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 16
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 210000000822 natural killer cell Anatomy 0.000 claims description 13
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 12
- 102100020986 DNA-binding protein RFX5 Human genes 0.000 claims description 12
- 101001075432 Homo sapiens DNA-binding protein RFX5 Proteins 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 claims description 11
- 102100026371 MHC class II transactivator Human genes 0.000 claims description 11
- 108700002010 MHC class II transactivator Proteins 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 10
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 9
- 102100021044 DNA-binding protein RFXANK Human genes 0.000 claims description 9
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 9
- 101001075464 Homo sapiens DNA-binding protein RFXANK Proteins 0.000 claims description 9
- 101001075466 Homo sapiens Regulatory factor X-associated protein Proteins 0.000 claims description 9
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 9
- 102100021043 Regulatory factor X-associated protein Human genes 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 230000003834 intracellular effect Effects 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 8
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 8
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 8
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 8
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 8
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 7
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 7
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 102000000905 Cadherin Human genes 0.000 claims description 6
- 108050007957 Cadherin Proteins 0.000 claims description 6
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims description 6
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims description 6
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 6
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 6
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 6
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims description 6
- 239000002872 contrast media Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 5
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims description 5
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 claims description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims description 5
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims description 5
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 claims description 5
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 claims description 5
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 5
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims description 5
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 claims description 5
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 claims description 5
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 claims description 5
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 claims description 5
- 101150069255 KLRC1 gene Proteins 0.000 claims description 5
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 claims description 5
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 claims description 5
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 claims description 5
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims description 5
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 5
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 5
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 claims description 5
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 210000002540 macrophage Anatomy 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 claims description 4
- 108010041384 HLA-DPA antigen Proteins 0.000 claims description 4
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 4
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 claims description 4
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 claims description 4
- 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 claims description 4
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 claims description 4
- 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 claims description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 4
- 102100026197 C-type lectin domain family 2 member D Human genes 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 102100038664 Fibrinogen-like protein 1 Human genes 0.000 claims description 3
- 102100031351 Galectin-9 Human genes 0.000 claims description 3
- 101710121810 Galectin-9 Proteins 0.000 claims description 3
- 101000912615 Homo sapiens C-type lectin domain family 2 member D Proteins 0.000 claims description 3
- 101001031635 Homo sapiens Fibrinogen-like protein 1 Proteins 0.000 claims description 3
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 claims description 3
- 102100035488 Nectin-2 Human genes 0.000 claims description 3
- 102100035487 Nectin-3 Human genes 0.000 claims description 3
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 210000004443 dendritic cell Anatomy 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 108010048507 poliovirus receptor Proteins 0.000 claims description 3
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 102100022436 CMRF35-like molecule 8 Human genes 0.000 claims 2
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 claims 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims 1
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 150000001413 amino acids Chemical group 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 16
- 102100029390 CMRF35-like molecule 1 Human genes 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 13
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 description 11
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 9
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 6
- 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 239000002619 cytotoxin Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 102100029382 CMRF35-like molecule 6 Human genes 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 101000990034 Homo sapiens CMRF35-like molecule 6 Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 3
- 102100038078 CD276 antigen Human genes 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 3
- 101000945335 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5B Proteins 0.000 description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 3
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 3
- 102100033628 Killer cell immunoglobulin-like receptor 2DL5B Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 229960004961 mechlorethamine Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 229930187843 Atramycin Natural products 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 2
- 108700012439 CA9 Proteins 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- 208000017815 Dendritic cell tumor Diseases 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 102100038083 Endosialin Human genes 0.000 description 2
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 description 2
- 101710088083 Glomulin Proteins 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 102100032530 Glypican-3 Human genes 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 2
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 2
- 101000884275 Homo sapiens Endosialin Proteins 0.000 description 2
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 description 2
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 2
- 101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 description 2
- 102000004569 Leukocyte Immunoglobulin-like Receptor B1 Human genes 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 101100181099 Mus musculus Klra1 gene Proteins 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 108700020467 WT1 Proteins 0.000 description 2
- 101150084041 WT1 gene Proteins 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 102000025171 antigen binding proteins Human genes 0.000 description 2
- 108091000831 antigen binding proteins Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000007983 brain glioma Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 108010087967 type I signal peptidase Proteins 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 102100040079 A-kinase anchor protein 4 Human genes 0.000 description 1
- 101710109924 A-kinase anchor protein 4 Proteins 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000017918 ADRB3 Human genes 0.000 description 1
- 108060003355 ADRB3 Proteins 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 description 1
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108010058905 CD44v6 antigen Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 101710178046 Chorismate synthase 1 Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102100038449 Claudin-6 Human genes 0.000 description 1
- 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 101710152695 Cysteine synthase 1 Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000012804 EPCAM Human genes 0.000 description 1
- 101150084967 EPCAM gene Proteins 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100023721 Ephrin-B2 Human genes 0.000 description 1
- 108010044090 Ephrin-B2 Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 1
- 101150032879 Fcrl5 gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000010451 Folate receptor alpha Human genes 0.000 description 1
- 108050001931 Folate receptor alpha Proteins 0.000 description 1
- 102000010449 Folate receptor beta Human genes 0.000 description 1
- 108050001930 Folate receptor beta Proteins 0.000 description 1
- 102100036939 G-protein coupled receptor 20 Human genes 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 102000044445 Galectin-8 Human genes 0.000 description 1
- 102100039554 Galectin-8 Human genes 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 208000003695 Histiocytic Necrotizing Lymphadenitis Diseases 0.000 description 1
- 206010069070 Histiocytic necrotising lymphadenitis Diseases 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 description 1
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 description 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 1
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 description 1
- 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 description 1
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 description 1
- 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101000954709 Homo sapiens Doublecortin domain-containing protein 2 Proteins 0.000 description 1
- 101001071355 Homo sapiens G-protein coupled receptor 20 Proteins 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000985516 Homo sapiens Hermansky-Pudlak syndrome 5 protein Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 101000840267 Homo sapiens Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 description 1
- 101000945337 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5A Proteins 0.000 description 1
- 101000945490 Homo sapiens Killer cell immunoglobulin-like receptor 3DL2 Proteins 0.000 description 1
- 101000945493 Homo sapiens Killer cell immunoglobulin-like receptor 3DL3 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000984197 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 2 Proteins 0.000 description 1
- 101000984206 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 6 Proteins 0.000 description 1
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 1
- 101000984185 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 5 Proteins 0.000 description 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101001065550 Homo sapiens Lymphocyte antigen 6K Proteins 0.000 description 1
- 101001018034 Homo sapiens Lymphocyte antigen 75 Proteins 0.000 description 1
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 description 1
- 101000721757 Homo sapiens Olfactory receptor 51E2 Proteins 0.000 description 1
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 description 1
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 description 1
- 101000589399 Homo sapiens Pannexin-3 Proteins 0.000 description 1
- 101000691463 Homo sapiens Placenta-specific protein 1 Proteins 0.000 description 1
- 101001064779 Homo sapiens Plexin domain-containing protein 2 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
- 101000665137 Homo sapiens Scm-like with four MBT domains protein 1 Proteins 0.000 description 1
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 description 1
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 1
- 101000714168 Homo sapiens Testisin Proteins 0.000 description 1
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 description 1
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- 101000808105 Homo sapiens Uroplakin-2 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000037977 Immune checkpoint ligands Human genes 0.000 description 1
- 108091008029 Immune checkpoint ligands Proteins 0.000 description 1
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 1
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 description 1
- 102100021317 Inducible T-cell costimulator Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102100034872 Kallikrein-4 Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000015282 Kikuchi-Fujimoto disease Diseases 0.000 description 1
- 102100033629 Killer cell immunoglobulin-like receptor 2DL5A Human genes 0.000 description 1
- 102100034840 Killer cell immunoglobulin-like receptor 3DL2 Human genes 0.000 description 1
- 102100034834 Killer cell immunoglobulin-like receptor 3DL3 Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100025586 Leukocyte immunoglobulin-like receptor subfamily A member 2 Human genes 0.000 description 1
- 102100025553 Leukocyte immunoglobulin-like receptor subfamily A member 6 Human genes 0.000 description 1
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 1
- 102100025577 Leukocyte immunoglobulin-like receptor subfamily B member 5 Human genes 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102100032129 Lymphocyte antigen 6K Human genes 0.000 description 1
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 101710195102 Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 108700012912 MYCN Proteins 0.000 description 1
- 101150022024 MYCN gene Proteins 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001026906 Mus musculus Killer cell lectin-like receptor subfamily B member 1B allele A Proteins 0.000 description 1
- 101001026894 Mus musculus Killer cell lectin-like receptor subfamily B member 1B allele B Proteins 0.000 description 1
- 101100181101 Mus musculus Klra3 gene Proteins 0.000 description 1
- 101100181104 Mus musculus Klra6 gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 206010028811 Natural killer-cell leukaemia Diseases 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241001452677 Ogataea methanolica Species 0.000 description 1
- 102100025128 Olfactory receptor 51E2 Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102100040891 Paired box protein Pax-3 Human genes 0.000 description 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 1
- 102100032364 Pannexin-3 Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102100026181 Placenta-specific protein 1 Human genes 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 102100031889 Plexin domain-containing protein 2 Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100032831 Protein ITPRID2 Human genes 0.000 description 1
- 102100037686 Protein SSX2 Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010037127 Pseudolymphoma Diseases 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241000724205 Rice stripe tenuivirus Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 1
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101150057140 TACSTD1 gene Proteins 0.000 description 1
- 108010032166 TARP Proteins 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102100036494 Testisin Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 102100027009 Toll-like receptor 10 Human genes 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102100038851 Uroplakin-2 Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 102000040856 WT1 Human genes 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 102100039490 X antigen family member 1 Human genes 0.000 description 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- HLDLMQYIUFMLLI-UHFFFAOYSA-N [N].C1=CC(N)=CC=C1C1=CC=C(N)C=C1 Chemical compound [N].C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HLDLMQYIUFMLLI-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical compound [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 description 1
- 229940125666 actinium-225 Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- JCXGWMGPZLAOME-OUBTZVSYSA-N bismuth-210 Chemical compound [210Bi] JCXGWMGPZLAOME-OUBTZVSYSA-N 0.000 description 1
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000006778 chronic monocytic leukemia Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 201000010918 connective tissue cancer Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000054957 human LILRB1 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 108010024383 kallikrein 4 Proteins 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical class CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 201000006402 rhabdoid cancer Diseases 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Definitions
- the present invention belongs to the field of immunotherapy. More specifically, the present invention relates to antibodies targeting LIR1 and their use in the prevention and/or treatment and/or diagnosis of diseases.
- LIR Leukocyte Immunoglobulin-like Receptor
- ITIMs Monocyte-macrophage inhibitory receptor
- the present invention aims to provide an antibody targeting LIR1 and its use in disease prevention and/or treatment and/or diagnosis.
- the present invention provides a LIR1 antibody, comprising: (1) CDR-L1 as shown in SEQ ID NO: 1, CDR-L2 as shown in SEQ ID NO: 2, and CDR-L2 as shown in SEQ ID NO: 2 : CDR-L3 shown in 3, CDR-H1 shown in SEQ ID NO:4, CDR-H2 shown in SEQ ID NO:5, CDR-H3 shown in SEQ ID NO:6; or ( 2) CDR-L1 as shown in SEQ ID NO: 10, CDR-L2 as shown in SEQ ID NO: 11, CDR-L3 as shown in SEQ ID NO: 12, as shown in SEQ ID NO: 13 CDR-H1, CDR-H2 as shown in SEQ ID NO:14, CDR-H3 as shown in SEQ ID NO:15.
- the LIR1 antibody is at least 90% identical to a light chain variable region selected from the group consisting of amino acid sequences set forth in SEQ ID NOs: 7 and 16, and with a variable region selected from the group consisting of SEQ ID NOs: 8 and 17
- the amino acid sequences shown have heavy chain variable regions that are at least 90% identical.
- the LIR1 antibody comprises a light chain variable region selected from the group consisting of SEQ ID NOs: 7 and 16 and a heavy chain variable region selected from the group consisting of SEQ ID NOs: 8 and 17. In one embodiment, the LIR1 antibody comprises a light chain variable region as set forth in SEQ ID NO:7 and a heavy chain variable region as set forth in SEQ ID NO:8; or as set forth in SEQ ID NO:16 The light chain variable region and the heavy chain variable region shown in SEQ ID NO: 17.
- amino acid sequence of the LIR1 antibody is selected from SEQ ID NOs: 9 and 18.
- the present invention also provides nucleic acid molecules encoding the above-mentioned LIR1 antibodies.
- the nucleic acid molecule encoding the LIR1 antibody has at least 90%, 91%, 92%, 93%, 94%, 95% of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 19-20 , 96%, 97%, 98%, 99%, 100% sequence identity, and the LIR1 antibody encoded by it can specifically bind to the LIR1 antigen.
- the nucleic acid molecule encoding the LIR1 antibody is selected from the group consisting of SEQ ID NOs: 19-20.
- the present invention also provides a multispecific antibody (preferably a bispecific or trispecific antibody) comprising the LIR1 antibody as described above and one or more second antibodies that specifically bind to other antigens An antibody or antigen-binding portion thereof.
- a multispecific antibody preferably a bispecific or trispecific antibody
- the second antibody or antigen-binding portion thereof may be in the form of any antibody or antibody fragment, such as a full-length antibody, Fab, Fab', (Fab') 2 , Fv, scFv, scFv-scFv, minibody, Diabodies or sdAbs.
- the present invention also provides vectors comprising nucleic acid molecules encoding the above-mentioned LIR1 antibodies or multispecific antibodies, and host cells expressing the LIR1 antibodies or multispecific antibodies.
- the present invention also provides a chimeric receptor comprising one or more NK inhibitory ligands, a transmembrane domain and a signaling domain, wherein the NK inhibitory ligand comprises as described above
- the chimeric receptor comprises two NK inhibitory ligands, wherein the first NK inhibitory ligand is a LIR1 antibody as described above and the second NK inhibitory ligand is selected from: (1) Antibodies or fragments thereof targeting the following NK inhibitory receptors: NKG2A, NKG2B, CD94, LIR2, LIR3, KIR2DL1, KIR2DL2/3, KIR3DL1, CEACAM1, LAIR1 and KLRG1; or (2) HLA-E, HLA-F, HLA-G, cadherin, collagen, OCIL, sialic acid, PD-L1, PD-L2, CD155, CD112, CD113, Gal-9, FGL1, and the NK inhibitory receptor binding domains they contain.
- the first NK inhibitory ligand is a LIR1 antibody as described above and the second NK inhibitory ligand is selected from: (1) Antibodies or fragments thereof targeting the following NK inhibitory receptors: NKG2A, NKG2B, CD94,
- the signaling domain in a chimeric receptor of the invention consists of one or more costimulatory domains. That is, do not comprise primary signaling domains, eg, primary signaling domains from FcR ⁇ , FcR ⁇ , CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD22, CD79a, CD79b, and CD66d.
- the signaling domain of the chimeric receptors of the invention may further comprise a primary signaling domain, eg, the CD3 ⁇ intracellular region.
- the present invention also provides nucleic acid molecules encoding a chimeric receptor targeting LIR1 as defined above, and vectors comprising said nucleic acid molecules.
- the present invention also provides an engineered immune cell expressing the chimeric receptor of the present invention comprising an LIR1 antibody, and wherein the expression of at least one MHC-related gene is inhibited or silenced.
- the MHC-related genes are selected from the group consisting of: HLA-A, HLA-B, HLA-C, B2M, HLA-DPA, HLA-DQ, HLA-DRA, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, CIITA and combinations thereof are preferably selected from HLA-A, HLA-B, HLA-C, B2M, RFX5, RFXAP, RFXANK, CIITA and combinations thereof.
- the engineered immune cells expressing the chimeric receptor comprising the LIR1 antibody of the present invention further comprise that the expression of at least one TCR/CD3 gene is inhibited or silenced, examples of which include For example TRAC, TRBC, CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD3 ⁇ .
- the engineered immune cells provided by the present invention further express chimeric antigen receptors targeting tumor antigens.
- the immune cells are selected from T cells, NK cells, NKT cells, macrophages, dendritic cells.
- the present invention also provides an antibody conjugate comprising the LIR1 antibody as defined in the present invention and a second functional structure, wherein the second functional structure is selected from Fc, radioisotopes, half-life prolonging Structural moieties, detectable labels and drugs.
- the half-life extending moiety is selected from: the half-life extending moiety is selected from the binding structure of albumin, the binding structure of transferrin, polyethylene glycol molecules, recombinant polyethylene glycol molecules, Human serum albumin, fragments of human serum albumin, and albumin polypeptides (including antibodies) that bind human serum albumin.
- the detectable label is selected from the group consisting of fluorophores, chemiluminescent compounds, bioluminescent compounds, enzymes, antibiotic resistance genes, and contrast agents.
- the drug is selected from cytotoxins and immunomodulators.
- the present invention also provides a detection kit comprising the antibody, multispecific antibody, antibody conjugate or chimeric receptor of the present invention.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the antibody, chimeric receptor, multispecific antibody, engineered cell or antibody conjugate of the present invention, and one or more pharmaceutical agents acceptable excipients.
- the present invention also provides a method of treating and/or preventing and/or diagnosing a disease associated with LIR1 expression, comprising administering to a subject an antibody, chimeric receptor, multispecific antibody as described above , antibody conjugates, engineered immune cells or pharmaceutical compositions.
- antibody has the broadest meaning as understood by those skilled in the art, and includes monoclonal antibodies (including whole antibodies), polyclonal antibodies, multivalent antibodies, multispecific antibodies (eg, bispecific antibodies) ), and antibody fragments or synthetic polypeptides carrying one or more CDR sequences capable of exhibiting the desired biological activity.
- the antibodies of the invention can be of any class (eg, IgG, IgE, IgM, IgD, IgA, etc.) or subclass (eg, IgGl, IgG2, IgG2a, IgG3, IgG4, IgAl, IgA2, etc.).
- Antibodies of the present invention also include recombinant antibodies, human antibodies, humanized antibodies, murine antibodies, chimeric antibodies, and antigen-binding portions thereof.
- an intact antibody comprises two heavy chains and two light chains linked together by disulfide bonds, each light chain being disulfide bonded to its respective heavy chain in a "Y"-shaped structure.
- Each heavy chain comprises a heavy chain variable region (VH) and a heavy chain constant region, wherein the heavy chain variable region comprises three complementarity determining regions (CDRs): CDR-H1, CDR-H2 and CDR-H3, the heavy chain constant
- the region contains three constant domains: CH1, CH2 and CH3.
- Each light chain includes a light chain variable region (VL) and a light chain constant region, wherein the light chain variable region includes three CDRs: CDR-L1, CDR-L2 and CDR-L3, and the light chain constant region includes a constant structure Domain CL.
- the CDRs are separated by more conserved framework regions (FRs).
- FRs conserved framework regions
- the variable region of the heavy/light chain is responsible for antigen recognition and binding, while the constant region mediates the binding of antibodies to host tissues or factors, including various cells of the immune system (such as effector cells) and the first of the classical complement system. one component.
- the boundaries of a given CDR or FR may vary depending on the protocol used for identification.
- the Kabat scheme is based on structural alignment
- the Chothia scheme is based on structural information.
- Both Kabat and Chothia's scheme numbering is based on the most common antibody region sequence lengths, where insertions are provided by intervening letters (eg "30a") and deletions occur in some antibodies. These two schemes place certain insertions and deletions ("indels”) in different positions, resulting in different numbers.
- the Contact scheme is based on the analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme.
- the AbM protocol is a compromise between the Kabat and Chothia definitions and is based on the protocol used by Oxford Molecular's AbM antibody modeling software.
- CDRs of a given antibody or regions thereof (eg, variable regions thereof) encompass the CDRs defined by any of the above schemes or other known schemes.
- CDR a particular CDR (eg, CDR3) is designated to contain a given amino acid sequence
- FRs of a given antibody or region thereof encompass the FRs defined by any of the above schemes or other known schemes.
- antibody fragment or "antigen-binding portion” encompasses only a portion of an intact antibody, typically comprising the antigen-binding site of the intact antibody and thus retaining the ability to bind antigen.
- antibody fragments in the present invention include, but are not limited to: Fab, Fab', F(ab')2, Fd fragment, Fd', Fv fragment, scFv, disulfide-linked Fv (sdFv), heavy Chain variable region (VH) or light chain variable region (VL), linear antibodies, "diabodies” with two antigen binding sites, single domain antibodies, nanobodies, natural ligands for said antigen or functional fragments, etc. Accordingly, "antibodies” of the present invention encompass antibody fragments as defined above.
- the LIR1 antibody of the invention is an scFv.
- Single-chain antibody and “scFv” are used interchangeably herein and refer to an antibody comprising an antibody heavy chain variable region (VH) and light chain variable region (VL) linked by a linker.
- the optimal length and/or amino acid composition of the linker can be selected.
- the length of the linker significantly affects the variable region folding and interaction of scFv. In fact, intrachain folding can be prevented if shorter linkers are used (eg between 5-10 amino acids).
- linker size and composition see, eg, Hollinger et al., 1993 Proc Natl Acad. Sci. U.S.A.
- the scFv can comprise VH and VL linked in any order, eg, VH-linker-VL or VL-linker-VH.
- the LIR1 antibody of the invention comprises (1) CDR-L1 as set forth in SEQ ID NO: 1, CDR-L2 as set forth in SEQ ID NO: 2, CDR-L2 as set forth in SEQ ID NO: 3 CDR-L3, CDR-H1 as set forth in SEQ ID NO:4, CDR-H2 as set forth in SEQ ID NO:5, CDR-H3 as set forth in SEQ ID NO:6; or (2) as SEQ ID NO:6 NO: CDR-L1 shown in SEQ ID NO: 10, CDR-L2 shown in SEQ ID NO: 11, CDR-L3 shown in SEQ ID NO: 12, CDR-H1 shown in SEQ ID NO: 13, CDR-H2 shown in SEQ ID NO: 14, CDR-H3 shown in SEQ ID NO: 15.
- the LIR1 antibody comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, A light chain variable region of 98%, 99%, 100% sequence identity, and having at least 90%, 91%, 92%, 93%, 94%, 90%, 91%, 92%, 93%, 94%, Heavy chain variable regions of 95%, 96%, 97%, 98%, 99%, 100% sequence identity.
- the LIR1 antibody comprises a light chain variable region selected from the group consisting of SEQ ID NOs: 7 and 16 and a heavy chain variable region selected from the group consisting of SEQ ID NOs: 8 and 17.
- the LIR1 antibody comprises a light chain variable region as shown in SEQ ID NO:7 and a heavy chain variable region as shown in SEQ ID NO:8; or a light chain as shown in SEQ ID NO:16 chain variable region and heavy chain variable region as set forth in SEQ ID NO:17.
- amino acid sequence of the LIR1 antibody is set forth in SEQ ID NO: 9 or 18.
- sequence identity refers to the degree to which two (nucleotide or amino acid) sequences have identical residues at the same positions in an alignment, and is usually expressed as a percentage. Preferably, identity is determined over the entire length of the sequences being compared. Therefore, two copies with the exact same sequence are 100% identical.
- sequence identity can be determined using several algorithms can be used to determine sequence identity, such as Blast (Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402), Blast2 (Altschul et al. (1990) J. Mol. Biol. 215: 403-410), Smith-Waterman (Smith et al. (1981) J. Mol. Biol. 147: 195-197) and ClustalW.
- the present invention also provides a multispecific antibody (preferably a bispecific or trispecific antibody) comprising the LIR1 antibody as described above, which further comprises one or more secondary antibodies that specifically bind to other antigens .
- a multispecific antibody preferably a bispecific or trispecific antibody
- the LIR1 antibody as described above, which further comprises one or more secondary antibodies that specifically bind to other antigens .
- multispecific refers to an antigen binding protein that has polyepitopic specificity (ie, is capable of specifically binding to two, three or more different epitopes on a biomolecule or capable of specific binds epitopes on two, three or more different biomolecules).
- bispecific means that an antigen binding protein has two different antigen binding specificities.
- the secondary antibody may be in any antibody or antibody fragment format, eg, a full-length antibody, Fab, Fab', (Fab') 2 , Fv, scFv, scFv-scFv, minibody, diabody, or sdAb.
- the invention relates to nucleic acid molecules encoding the LIR1 antibodies or multispecific antibodies of the invention.
- the nucleic acid of the present invention may be RNA, DNA or cDNA.
- the nucleic acid of the invention is a substantially isolated nucleic acid.
- the nucleic acid molecule encoding the LIR1 antibody has at least 90%, 91%, 92%, 93%, 94%, 95%, 96% of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 19-20 %, 97%, 98%, 99%, 100% sequence identity, and the LIR1 antibody encoded by it can specifically bind to LIR1 antigen.
- the nucleic acid molecules encoding the LIR1 antibodies are shown in SEQ ID NOs: 19-20.
- the nucleic acid of the present invention may also be in the form of, may be present in and/or be part of a vector, such as a plasmid, cosmid or YAC.
- the vector may in particular be an expression vector, ie a vector that provides for expression of the LIR1 antibody in vitro and/or in vivo (ie in a suitable host cell, host organism and/or expression system).
- the expression vector typically comprises at least one nucleic acid molecule of the invention operably linked to one or more suitable expression control elements (eg, promoters, enhancers, terminators, etc.). Selection of such regulatory elements and their sequences for expression in a particular host is well known to those skilled in the art. Specific examples of regulatory elements and other elements useful or necessary for the expression of the LIR1 antibodies of the invention include, but are not limited to, promoters, enhancers, terminators, integration factors, selectable markers, leader sequences, reporter genes.
- the present invention also provides host cells expressing the LIR1 antibodies, multispecific antibodies of the present invention and/or containing the nucleic acids or vectors of the present invention.
- Preferred host cells of the present invention are bacterial cells, fungal cells or mammalian cells.
- Suitable bacterial cells include gram-negative bacterial strains (eg, Escherichia coli, Proteus, and Pseudomonas strains) and gram-positive bacterial strains (eg, Bacillus Bacillus strains, Streptomyces strains, Staphylococcus strains and Lactococcus strains).
- gram-negative bacterial strains eg, Escherichia coli, Proteus, and Pseudomonas strains
- gram-positive bacterial strains eg, Bacillus Bacillus strains, Streptomyces strains, Staphylococcus strains and Lactococcus strains.
- Suitable fungal cells include cells of species of Trichoderma, Neurospora and Aspergillus; or Saccharomyces (eg Saccharomyces cerevisiae), Saccharomyces (such as Schizosaccharomyces pombe), Pichia (such as Pichia pastoris and Pichia methanolica) and Hansen A cell of a species of the genus Hansenula.
- Saccharomyces eg Saccharomyces cerevisiae
- Saccharomyces such as Schizosaccharomyces pombe
- Pichia such as Pichia pastoris and Pichia methanolica
- Suitable mammalian cells include, for example, HEK293 cells, CHO cells, BHK cells, HeLa cells, COS cells, and the like.
- amphibian cells insect cells, plant cells, and any other cell in the art for expressing heterologous proteins may also be used in the present invention.
- the present invention also provides a chimeric receptor comprising the LIR1 antibody as described above. Since LIR1 is an NK inhibitory receptor, chimeric receptors comprising LIR1 antibodies can be used to inhibit the killing of NK cells.
- the present invention provides a chimeric receptor comprising one or more NK inhibitory ligands, a transmembrane domain, and a signaling domain, wherein the NK inhibitory ligand comprises as described above
- the chimeric receptor comprises multiple NK inhibitory ligands, eg, two NK inhibitory ligands, wherein the first NK inhibitory ligand is a LIR1 antibody as described above and the second NK inhibitory ligand Sexual ligands are antibodies or fragments thereof that target other NK inhibitory receptors, and/or natural ligands for other NK inhibitory receptors or NK inhibitory receptor binding regions they comprise.
- the second NK inhibitory ligand is an antibody or fragment thereof that targets the following NK inhibitory receptors: NKG2/CD94 components (eg, NKG2A, NKG2B, CD94); Killer cell Ig-like Receptor (KIR) family members (eg, KIR2DL1, KIR2DL2/3, KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL2, and KIR3DL3); leukocyte Ig-like receptor (LIR) family members (eg, LIR2, LIR3, LIR5, and LIR8); NK cells are affected by Body protein 1 (NKR-P1) family members (eg, NKR-P1B and NKR-P1D); immune checkpoint receptors (eg, PD-1, TIGIT and CD96, TIM3, LAG3); carcinoembryonic antigen-associated cell adhesion molecule 1 (CEACAM1); sialic acid-binding immunoglobulin-like lectin (SIGLEC)
- the second NK inhibitory ligand is selected from antibodies or fragments thereof targeting the following NK inhibitory receptors: NKG2A, NKG2B, CD94, LIR2, LIR3, KIR2DL1, KIR2DL2/3, KIR3DL1, CEACAM1, LAIR1 and KLRG1. Still more preferably, the second NK inhibitory ligand is selected from the group consisting of antibodies or fragments thereof targeting the following NK inhibitory receptors: NKG2A, CD94, KIR2DL1, KIR2DL2/3, KIR3DL1, CEACAM1, LAIR1 and KLRG1.
- the second NK inhibitory ligand is a natural ligand of another NK inhibitory receptor or the NK inhibitory receptor binding region it comprises, eg, HLA-E, HLA-F, HLA-G , cadherin, collagen, OCIL, sialic acid, immune checkpoint ligands (eg PD-L1/PD-L2, CD155, CD112, CD113, Gal-9, FGL1, etc.), and the NK inhibitory receptors they contain body binding region.
- the second NK inhibitory ligand is selected from HLA-E, HLA-F, HLA-G, cadherin, PD-L1, PD-L2, or the NK inhibitory receptor binding regions they comprise.
- the second NK inhibitory ligand is selected from HLA-E extracellular domain, HLA-G extracellular domain, E-cadherin extracellular domain, PD-L1 extracellular domain and PD-L2 extracellular domain Area. More preferably, the second NK inhibitory ligand is the E-cadherin extracellular domain comprising EC1 and EC2, more preferably EC1, EC2, EC3, EC4 and EC5.
- transmembrane domain refers to a polypeptide structure that enables expression of a chimeric receptor on the surface of immune cells (eg, lymphocytes, NK cells, or NKT cells) and directs the cellular response of the immune cells against target cells .
- the transmembrane domain can be natural or synthetic, and can be derived from any membrane-bound or transmembrane protein.
- the transmembrane domain is capable of signaling when the chimeric receptor binds to the target antigen.
- Transmembrane domains particularly useful in the present invention may be derived from, for example, TCR ⁇ chain, TCR ⁇ chain, TCR ⁇ chain, TCR ⁇ chain, CD3 ⁇ subunit, CD3 ⁇ subunit, CD3 ⁇ subunit, CD3 ⁇ subunit, CD45, CD4, CD5, CD8 ⁇ , CD9, CD16, CD22, CD33, CD28, CD37, CD64, CD80, CD86, CD134, CD137, CD154 and their functional fragments.
- the transmembrane domain may be synthetic and may contain predominantly hydrophobic residues such as leucine and valine.
- the transmembrane domain is derived from the CD8 alpha chain or CD28, which is at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% of the amino acid sequence shown in SEQ ID NO: 24 or 26 % or 99% or 100% sequence identity, or its coding sequence has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% with the nucleic acid molecule shown in SEQ ID NO: 25 or 27 or 99% or 100% sequence identity.
- costimulatory domain refers to an intracellular functional signaling domain from a costimulatory molecule that comprises the entire intracellular portion of the costimulatory molecule, or a functional fragment thereof.
- costimulatory molecule refers to a cognate binding partner that specifically binds to a costimulatory ligand on a T cell, thereby mediating a costimulatory response (eg, proliferation) of the T cell.
- Costimulatory molecules include, but are not limited to, MHC class 1 molecules, BTLA and Toll ligand receptors.
- Non-limiting examples of costimulatory domains of the invention include, but are not limited to, intracellular regions derived from the following proteins: TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD8, CD18 (LFA-1), CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40), CD137 (4-1BB), CD270 (HVEM), CD272 (BTLA), CD276 ( B7-H3), CD278 (ICOS), CD357 (GITR), DAP10, LAT, NKG2C, SLP76, PD-1, LIGHT, TRIM and ZAP70.
- the costimulatory domain of the CAR of the present invention is from 4-1BB, CD28 or 4-1BB+CD28.
- the 4-1BB costimulatory domain is at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% of the amino acid sequence set forth in SEQ ID NO:27 % sequence identity, or its coding sequence has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence with the nucleic acid molecule shown in SEQ ID NO: 28 identity.
- the CD28 costimulatory domain has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% of the amino acid sequence set forth in SEQ ID NO:25 Sequence identity, or its coding sequence, has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the nucleic acid molecule set forth in SEQ ID NO:26 .
- the signaling domain consists of one or more costimulatory domains (ie, does not comprise a primary signaling domain, eg, from FcR ⁇ , FcR ⁇ , CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD22, CD79a , the primary signaling domains of CD79b and CD66d).
- the signaling domain of a chimeric receptor of the invention may also comprise a primary signaling domain, such as the CD3 ⁇ intracellular region.
- the CD3 ⁇ intracellular region is at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% of the amino acid sequence shown in SEQ ID NO: 29 or 31 or 100% sequence identity, or its coding sequence has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% with the nucleic acid molecule shown in SEQ ID NO: 30 or 32 or 100% sequence identity.
- the chimeric receptors of the invention may further comprise a hinge region between the antibody and the transmembrane domain.
- the term "hinge region” generally refers to any oligopeptide or polypeptide that functions to link a transmembrane domain and an antibody. Specifically, the hinge region serves to provide greater flexibility and accessibility to the ligand binding domain.
- the hinge region may comprise up to 300 amino acids, preferably 10 to 100 amino acids and most preferably 25 to 50 amino acids.
- the hinge region can be derived in whole or in part from a native molecule, such as in whole or in part from the extracellular region of CD8, CD4 or CD28, or in whole or in part from an antibody constant region.
- the hinge region may be a synthetic sequence corresponding to a naturally occurring hinge sequence, or may be a fully synthetic hinge sequence.
- the hinge region comprises a CD8 ⁇ , CD28, Fc ⁇ RIII ⁇ receptor, IgG4 or IgG1 hinge region portion, more preferably a CD8 ⁇ , CD28 or IgG4 hinge, which is set forth in SEQ ID NO: 37, 39 or 41
- the amino acid sequence has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity, or its coding sequence is identical to that of SEQ ID NO: 38, 40 or 42
- the nucleotide sequences shown have at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity.
- the CR of the invention may also comprise a signal peptide such that when expressed in a cell, eg, a T cell, the nascent protein is directed to the endoplasmic reticulum and subsequently to the cell surface.
- the core of the signal peptide may contain a long segment of hydrophobic amino acids that has a tendency to form a single alpha-helix.
- signal peptidases At the end of the signal peptide, there is usually a segment of amino acids that is recognized and cleaved by signal peptidases.
- the signal peptidase can cleave during or after translocation to generate the free signal peptide and mature protein. Then, the free signal peptide is digested by specific proteases.
- Signal peptides useful in the present invention are well known to those skilled in the art, for example signal peptides derived from B2M, CD8 ⁇ , IgG1, GM-CSFR ⁇ , and the like.
- the signal peptide useful in the present invention is from B2M or CD8 ⁇ , which is at least 70%, preferably at least 80%, more preferably at least 90%, 95% of the amino acid sequence shown in SEQ ID NO: 33 or 35 , 97% or 99% or 100% sequence identity, or its coding sequence has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity.
- the CR comprises a LIR1 antibody as provided herein or a multispecific antibody comprising the LIR1 antibody, a CD8 ⁇ transmembrane region, and a signaling domain comprising the group consisting of CD28 and The costimulatory domain of 4-1BB.
- the signaling domain consists of a costimulatory domain selected from CD28 and 4-1BB.
- the signaling domain further comprises the CD3 ⁇ intracellular domain.
- the CAR may further comprise a signal peptide from B2M, CD8 ⁇ , IgG1 or GM-CSFR ⁇ .
- the present invention also provides nucleic acid molecules encoding a chimeric receptor targeting LIR1 as defined above, and vectors comprising said nucleic acid molecules.
- vector is a nucleic acid molecule used as a vehicle for the transfer of (exogenous) genetic material into a host cell, in which the nucleic acid molecule can eg be replicated and/or expressed.
- Vectors generally include targeting vectors and expression vectors.
- a "targeting vector” is a medium that delivers an isolated nucleic acid to the interior of a cell by, for example, homologous recombination or a hybrid recombinase using a specific targeting sequence at the site.
- An “expression vector” is a vector used for the transcription of heterologous nucleic acid sequences, such as those encoding the chimeric receptor polypeptides of the invention, in suitable host cells, and the translation of their mRNAs.
- the vectors of the present invention include, but are not limited to, plasmids, viruses (eg, retroviruses, lentiviruses, adenoviruses, vaccinia virus, Rous sarcoma virus (RSV, polyoma virus, and adeno-associated virus (AAV)), and the like ), phages, phagemids, cosmids, and artificial chromosomes (including BACs and YACs).
- the vector itself is usually a nucleic acid molecule, usually a DNA sequence containing an insert (transgene) and a larger sequence that serves as the "backbone" of the vector.
- the VL vector typically also contains an origin of autonomous replication in the host cell (if stable expression of the polynucleotide is desired), a selectable marker, and a restriction enzyme cleavage site (eg, a multiple cloning site, MCS).
- the vector may additionally contain a promoter, multiple elements such as polyadenylated tails (polyA), 3'UTRs, enhancers, terminators, insulators, operons, selectable markers, reporter genes, targeting sequences and/or protein purification tags.
- polyA polyadenylated tails
- the vector is an in vitro transcribed vector.
- LIR1 can bind to HLA-I molecules, it inhibits the activation of immune cells such as NK cells. Therefore, the introduction of exogenous LIR1 antibodies can inhibit the killing effect of NK cells by binding to LIR1, which is especially useful in certain situations (such as the deletion of HLA-I molecules or the preparation of universal CAR-T cells). .
- the present invention also provides an engineered immune cell expressing a chimeric receptor of the present invention comprising a LIR1 antibody, and wherein the expression of at least one MHC-related gene is inhibited or silenced.
- MHC-related genes include MHC genes themselves (eg, MHC-class I molecules and MHC-class II molecules), as well as genes that interact with or regulate expression of MHC genes.
- MHC-class I molecules include, but are not limited to, HLA-A, HLA-B, HLA-C, B2M.
- MHC-class II molecules include, but are not limited to, HLA-DPAl, HLA-DQA1, and HLA-DRA.
- genes that interact with or regulate expression of MHC genes include, but are not limited to, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, and CIITA.
- suppressing or silencing the expression of MHC-related genes refers to suppressing or silencing the expression of one or more genes selected from the group consisting of: HLA-A, HLA-B, HLA-C, B2M, HLA-DPA, HLA-DQ, HLA-DRA, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, CIITA and combinations thereof, preferably selected from HLA-A, HLA-B, HLA-C, B2M, RFX5 , RFXAP, RFXANK, CIITA, and combinations thereof.
- the engineered immune cells expressing the chimeric receptor comprising the LIR1 antibody of the present invention further comprise that the expression of at least one TCR/CD3 gene is inhibited or silenced, examples of which include For example TRAC, TRBC, CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD3 ⁇ .
- the engineered immune cells expressing the chimeric receptors of the present invention comprise suppressed or silenced expression of at least one TCR/CD3 gene and at least one MHC-related gene, wherein the at least one A kind of TCR/CD3 gene is selected from TRAC, TRBC, CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD3 ⁇ and their combination; Said at least one MHC-related gene is selected from HLA-A, HLA-B, HLA-C, B2M, HLA-DPA , HLA-DQ, HLA-DRA, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, CIITA and combinations thereof, preferably selected from HLA-A, HLA-B, HLA-C, B2M, RFX5, RFXAP, RFXANK, CIITA and their combination.
- the at least one TCR/CD3 gene is selected from the group consisting of TRAC, TRBC, and combinations thereof
- the at least one MHC-related gene is selected from the group consisting of B2M, RFX5, RFXAP, RFXANK, CIITA, and combinations thereof .
- the expression of TRAC or TRBC, and B2M of the engineered immune cells is inhibited or silenced.
- the expression of TRAC or TRBC, and CIITA of the engineered immune cells is inhibited or silenced.
- the expression of TRAC or TRBC, B2M and CIITA of the engineered immune cells is inhibited or silenced.
- the expression of TRAC or TRBC, B2M and RFX5 of the engineered immune cells is inhibited or silenced.
- Methods of inhibiting gene expression or silencing genes include, but are not limited to, DNA fragmentation mediated by, for example, meganucleases, zinc finger nucleases, TALE nucleases, or Cas enzymes in the CRISPR system, or by Antisense oligonucleotides, RNAi, shRNA and other technologies inactivate genes.
- the engineered immune cells provided by the present invention further express chimeric antigen receptors targeting tumor antigens.
- the chimeric antigen receptor targets a tumor antigen selected from the group consisting of TSHR, CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, mesothelin, IL-11Ra, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR- ⁇ , SSEA-4, CD20, Folate receptor ⁇ , ERBB2(Her2/neu), MUC1, EGFR, NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gplOO, bcr -abl, tyrosinase, EphA2, Fucosyl GM1, sLe, GM3,
- the target is selected from: CD19, CD20, CD22, BAFF-R, CD33, EGFRvIII, BCMA, GPRC5D, PSMA, ROR1, FAP, ERBB2(Her2/neu), MUCl, EGFR, CAIX, WT1, NY- ESO-1, CD79a, CD79b, GPC3, Claudin18.2, NKG2D and any combination thereof.
- the CAR of the present invention can be designed to include a ligand binding domain specific for that antigen.
- an antibody to CD19 can be used as the ligand binding domain of the invention.
- the term "immune cell” refers to any cell of the immune system that has one or more effector functions (eg, cytotoxic cell killing activity, secretion of cytokines, induction of ADCC and/or CDC).
- the immune cells can be T cells, macrophages, dendritic cells, monocytes, NK cells, and/or NKT cells.
- the immune cells are derived from stem cells, such as adult stem cells, embryonic stem cells, umbilical cord blood stem cells, progenitor cells, bone marrow stem cells, induced pluripotent stem cells, totipotent stem cells, or hematopoietic stem cells, and the like.
- the immune cells are T cells.
- the T cells can be any T cells, such as T cells cultured in vitro, eg, primary T cells, or T cells from T cell lines cultured in vitro, such as Jurkat, SupT1, etc., or T cells obtained from a subject. Examples of subjects include humans, dogs, cats, mice, rats, and transgenic species thereof. T cells can be obtained from a variety of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from sites of infection, ascites, pleural effusion, spleen tissue, and tumors. T cells can also be concentrated or purified.
- T cells can be at any stage of development, including, but not limited to, CD4+/CD8+ T cells, CD4+ helper T cells (eg, Th1 and Th2 cells), CD8+ T cells (eg, cytotoxic T cells), tumor-infiltrating cells, memory T cells, naive T cells, ⁇ -T cells, ⁇ -T cells, etc.
- the immune cells are human T cells.
- T cells can be obtained from the blood of a subject using a variety of techniques known to those of skill in the art, such as Ficoll separation.
- Nucleic acid sequences encoding chimeric receptors can be introduced into immune cells using conventional methods known in the art (eg, by transduction, transfection, transformation, etc.).
- Transfection is the process of introducing a nucleic acid molecule or polynucleotide, including a vector, into a target cell.
- An example is RNA transfection, the process of introducing RNA (eg, in vitro transcribed RNA, ivtRNA) into a host cell.
- RNA transfection the process of introducing RNA (eg, in vitro transcribed RNA, ivtRNA) into a host cell.
- the term is mainly used for non-viral methods in eukaryotic cells.
- transduction is generally used to describe virus-mediated transfer of nucleic acid molecules or polynucleotides.
- Transfection of animal cells typically involves opening transient pores or "holes" in the cell membrane to allow uptake of material.
- Transfection can be performed using calcium phosphate, by electroporation, by cell extrusion, or by mixing cationic lipids with materials to create liposomes that fuse with cell membranes and deposit their cargo inside.
- Exemplary techniques for transfecting eukaryotic host cells include lipid vesicle-mediated uptake, heat shock-mediated uptake, calcium phosphate-mediated transfection (calcium phosphate/DNA co-precipitation), microinjection, and electroporation. perforation.
- transformation is used to describe the non-viral transfer of nucleic acid molecules or polynucleotides (including vectors) into bacteria, but also into non-animal eukaryotic cells (including plant cells).
- transformation is the genetic alteration of a bacterial or non-animal eukaryotic cell, which is produced by the direct uptake of the cell membrane from its surroundings and subsequent incorporation of exogenous genetic material (nucleic acid molecules). Conversion can be achieved by manual means.
- the cells or bacteria must be in a competent state.
- techniques can include heat shock-mediated uptake, fusion of bacterial protoplasts with intact cells, microinjection, and electroporation.
- the present invention provides a plurality of engineered immune cells, wherein one immune cell expresses a chimeric receptor described herein and another immune cell expresses a second chimeric receptor targeting other NK inhibitory receptors combined receptors.
- the second chimeric receptor comprises a second NK inhibitory ligand, a transmembrane domain, and a signaling domain, wherein the second NK inhibitory ligand, the transmembrane domain, and a signaling domain Conductive domains are defined as described in the "Chimeric Receptors" section.
- one immune cell is engineered to express a chimeric receptor comprising a LIR1 antibody
- another immune cell is engineered to express a chimeric antigen receptor targeting a tumor antigen.
- the plurality of engineered immune cells can be administered together or separately.
- the plurality of immune cells may be in the same composition or in different compositions. Exemplary compositions of cells include those described in the following sections of this application.
- the present invention provides an antibody conjugate comprising a LIR1 antibody as defined in the present invention and a second functional structure, wherein the second functional structure is selected from Fc, a radioisotope, a half-life extending moiety , detectable markers and drugs.
- the present invention provides an antibody conjugate comprising a LIR1 antibody as defined in the present invention and an Fc.
- Fc is used to define the C-terminal region of an immunoglobulin heavy chain, which includes native Fc and variant Fc.
- Native Fc refers to a molecule or sequence comprising a non-antigen-binding fragment, whether in monomeric or multimeric form, produced by digestion of an intact antibody.
- the source of immunoglobulins for the production of native Fc is preferably derived from humans.
- Native Fc fragments are composed of monomeric polypeptides that can be linked in dimeric or multimeric form by covalent linkages (eg, disulfide bonds) and non-covalent linkages.
- native Fc the disulfide-linked dimer produced by papain digestion of IgG (see Ellison et al. (1982) Nucleic Acids Res. 10:4071-9).
- native Fc the disulfide-linked dimer produced by papain digestion of IgG (see Ellison et al. (1982) Nucleic Acids Res. 10:4071-9).
- native Fc as used herein generally refers to monomeric, dimeric and multimeric forms.
- “Variant Fc” refers to an amino acid sequence that differs from that of a “native” or “wild-type” Fc due to at least one "amino acid modification” as defined herein, also referred to as an "Fc variant".
- “Fc” also includes single-chain Fc (scFc), ie, a single-chain Fc consisting of two Fc monomers linked by a polypeptide linker, which is capable of naturally folding into a functional dimeric Fc region.
- the Fc is preferably a human immunoglobulin Fc, more preferably a human IgGl Fc.
- the present invention provides an antibody conjugate comprising a LIR1 antibody as defined in the present invention and a radioisotope.
- radioisotopes useful in the present invention include, but are not limited to, At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 , 99m Tc, 123 I, 18 F and 68 Ga.
- the present invention provides an antibody conjugate comprising the LIR1 antibody as defined in the present invention and a half-life extending moiety selected from the group consisting of the binding structure of albumin, the Binding structures, polyethylene glycol molecules, recombinant polyethylene glycol molecules, human serum albumin, fragments of human serum albumin, and white polypeptides (including antibodies) that bind human serum albumin.
- the present invention provides an antibody conjugate comprising a LIR1 antibody as defined in the present invention and a detectable label.
- detectable label herein means a compound that produces a detectable signal.
- the detectable label can be an MRI contrast agent, a scintigraphic contrast agent, an X-ray imaging contrast agent, an ultrasound contrast agent, an optical imaging contrast agent.
- detectable labels examples include fluorophores (such as fluorescein, Alexa, or cyanine), chemiluminescent compounds (such as luminol), bioluminescent compounds (such as luciferase or alkaline phosphatase), enzymes (such as Root peroxidase, glucose-6-phosphatase, ⁇ -galactosidase), antibiotics (such as kanamycin, ampicillin, chloramphenicol, tetracycline, etc.) resistance genes and contrast agents (such as nanoparticles or gadolinium).
- fluorophores such as fluorescein, Alexa, or cyanine
- chemiluminescent compounds such as luminol
- bioluminescent compounds such as luciferase or alkaline phosphatase
- enzymes such as Root peroxidase, glucose-6-phosphatase, ⁇ -galactosidase
- antibiotics such as kanamycin, ampicillin, chloramphenicol, t
- the present invention provides an antibody conjugate comprising a LIR1 antibody as defined in the present invention and a drug, such as a cytotoxin or an immunomodulatory agent (ie, an antibody drug conjugate), conjugated to the LIR1 antibody thing).
- a drug such as a cytotoxin or an immunomodulatory agent (ie, an antibody drug conjugate), conjugated to the LIR1 antibody thing).
- the drug is covalently attached to the antibody and usually relies on a linker.
- the drug is a cytotoxin.
- the drug is an immunomodulatory agent.
- cytotoxins include, but are not limited to, methotrexate, aminopterin, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil, dacarbazine, nitrogen mustard, thiotepa, benzidine Nitrogen mustard, melphalan, carmustine (BSNU), lomustine (CCNU), 1-methylnitrosourea, cyclophosphamide, nitrogen mustard, busulfan, dibromomannitol, chain Zocin, mitomycin, cis-dichlorodiamineplatinum (II) (DDP), cisplatin, carboplatin, zorubicin, doxorubicin, detorubicin, caminomycin, Darubicin, epirubicin, mitoxantrone, actinomycin D, bleomycin, calicheamicin, glaremycin, atramycin (AMC), vincristine, vinblastine, Paclitaxel,
- immunomodulators include, but are not limited to, ganciclovir, etanercept, tacrolimus, sirolimus, vortexporine, cyclosporine, rapamycin, cyclophosphamide, azathioprine , mycophenolate mofetil, methotrexate, glucocorticoids and their analogs, cytokines, stem cell growth factors, lymphotoxins, tumor necrosis factor (TNF), hematopoietic factors, interleukins (such as IL-1, IL-2, IL-3, IL-6, IL-10, IL-12, IL-18 and IL-21), colony stimulating factors such as G-CSF and (GM-CSF), interferons such as interferon-alpha, interferon interferon-beta and interferon-gamma), stem cell growth factors designated "S1 factor", erythropoietin and thrombopoietin, or a combination thereof.
- TNF tumor nec
- the present invention also provides a detection kit comprising the antibody, multispecific antibody, chimeric receptor or antibody conjugate of the present invention.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the antibody, multispecific antibody, chimeric receptor, engineered immune cell or antibody conjugate of the present invention, and one or more Pharmaceutically acceptable excipients.
- the term "pharmaceutically acceptable excipient” means pharmacologically and/or physiologically compatible with the subject and the active ingredient (ie, capable of eliciting the desired therapeutic effect without causing any inconvenience desired local or systemic effect) carriers and/or excipients, which are well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995).
- Examples of pharmaceutically acceptable excipients include, but are not limited to, fillers, binders, disintegrants, coatings, adsorbents, antiadherents, glidants, antioxidants, flavoring agents, colorants, Sweeteners, solvents, co-solvents, buffers, chelating agents, surfactants, diluents, wetting agents, preservatives, emulsifiers, coating agents, isotonic agents, absorption delaying agents, stabilizers and tonicity modifiers . It is known to those skilled in the art to select suitable excipients to prepare the desired pharmaceutical compositions of the present invention.
- excipients for use in the pharmaceutical compositions of the present invention include saline, buffered saline, dextrose and water.
- suitable excipients depends, among other things, on the active agent used, the disease to be treated and the desired dosage form of the pharmaceutical composition.
- compositions according to the present invention may be suitable for administration by various routes. Typically, administration is accomplished parenterally.
- Parenteral delivery methods include topical, intraarterial, intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, intrauterine, intravaginal, sublingual or intranasal administration.
- compositions according to the invention can also be prepared in various forms, such as solid, liquid, gaseous or lyophilized forms, in particular ointments, creams, transdermal patches, gels, powders, tablets, solutions, gaseous In the form of aerosols, granules, pills, suspensions, emulsions, capsules, syrups, elixirs, extracts, tinctures or liquid extracts, or in a form particularly suitable for the desired method of administration.
- Processes known in the present invention for the manufacture of pharmaceuticals may include, for example, conventional mixing, dissolving, granulating, dragee-making, milling, emulsifying, encapsulating, entrapping, or lyophilizing processes.
- Pharmaceutical compositions comprising immune cells such as those described herein are typically provided in solution and preferably comprise a pharmaceutically acceptable buffer.
- compositions according to the present invention may also be administered in combination with one or more other agents suitable for the treatment and/or prevention of the disease to be treated.
- agents suitable for combination include known anticancer drugs such as cisplatin, maytansine derivatives, rachelmycin, calicheamicin, docetaxel, etoposide , gemcitabine, ifosfamide, irinotecan, melphalan, mitoxantrone, sorfimer sodium photofrin II, temozolomide, topotecan, trimetate glucuronate, auristatin E, vincristine and doxorubicin; peptide cytotoxins such as ricin, diphtheria toxin, Pseudomonas bacterial exotoxin A, DNase and RNase; radionuclides such as iodine 131, rhenium 186, indium 111, iridium 90, bismuth 210 and 213, act
- the present invention also provides a method of treating and/or preventing and/or diagnosing a disease associated with LIR1 expression, comprising administering to a subject an antibody, chimeric receptor, multispecific antibody as described above , antibody conjugates, engineered immune cells or pharmaceutical compositions.
- diseases associated with LIR1 expression include, but are not limited to: acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, erythroleukemia, acute megakaryocytic leukemia; chronic leukemia, such as Chronic myeloid leukemia, chronic lymphocytic leukemia, chronic monocytic leukemia; and other special types of leukemia such as hairy cell leukemia, prolymphocytic leukemia, plasma cell leukemia, adult T-cell leukemia, eosinophilic leukemia, basophilic leukemia myeloid leukemia, etc.), blastic plasmacytoid dendritic cell tumor, malignant lymphoproliferative disorders, Waldenstrom macroglobulinemia, lymphomas (including Hodgkin lymphoma and non-Hodgkin lymphoma such as B Cell lymphomas (including low-grade/follicular non-Hodgkin lymphom
- small cell lung cancer non-small cell lung cancer, glandular lung and squamous lung cancer
- melanoma myeloma, neuroblastoma
- oral cancer e.g., lips, tongue, mouth, and pharynx
- ovarian cancer pancreatic cancer, prostate cancer, mesothelioma, retinoblastoma, rhabdoid Sarcoma, rectal cancer, cancer of the respiratory system, salivary gland cancer, skin cancer, squamous cell cancer, gastric cancer, testicular cancer, thyroid cancer, uterine or endometrial cancer, malignant tumor of the urinary system, vulvar cancer.
- the diseases treated by the engineered immune cells or the pharmaceutical composition of the present invention are selected from: monocyte/macrophage dysfunction diseases, leukemia, lymphoma, multiple myeloma, brain glioma, pancreatic cancer, gastric cancer and the like.
- the anti-LIR1 antibody-containing chimeric receptor of the invention and the tumor antigen-targeting chimeric antigen receptor are co-expressed in immune cells or are administered in combination with immune cells expressing both, respectively.
- the diseases that can be treated depend on the tumor antigen targeted by the chimeric antigen receptor.
- a chimeric receptor of the invention comprising an anti-LIR1 antibody
- the diseases that can be treated are diseases associated with CD19 expression, such as B-cell malignancies, including Acute lymphocytic leukemia (B-ALL), chronic B-lymphocytic leukemia (B-CLL), B-cell Hodgkin's lymphoma (B-HL) and non-Hodgkin's lymphoma (B-NHL), etc.
- a chimeric receptor comprising an anti-LIR1 antibody is used to inhibit killing of reinfused engineered immune cells by NK cells, while a chimeric antigen receptor is used to target cell killing through binding to tumor antigens .
- Figure 1 shows the level of scFv expression of UNKi-T cells containing LIR1 antibody.
- Figure 2 Shows the inhibitory effect of LIR1 antibody-containing UNKi-T cells on NK cell killing. Two-way ANOVA was used for analysis and statistical analysis was performed with T test. ** Indicates that the P value is less than 0.01, reaching a significant level.
- the sequence containing the extracellular region of the LIR1 protein was cloned into a pCP vector with a His tag, and the correctly sequenced plasmid was transiently infected with CHO cells. After culturing for 8-10 days, the cell culture medium was harvested, and the protein was purified by affinity chromatography to obtain The extracellular domain of human LIR1 protein as an immunogen.
- mice 6-8 week old female Balb/c mice were used for primary and booster immunization, and ELISA and FACS were used to detect the antibody titer and specificity of protein immunogen in serum. After comprehensive evaluation, mice were given the last booster immunization. Mice were sacrificed after 3-4 days, spleen cells were collected, mixed with mouse myeloma cells (SP2/0) in a certain proportion, and the proliferated hybridoma cells were identified by FACS and ELISA, and positive cell lines were screened. . After several rounds of subcloning identification, two hybridoma cells that can stably secrete LIR1 antibody were finally obtained, and the LIR1-1 and KIR1-2 antibodies were obtained after the antibodies in the supernatants of the two cell lines were purified.
- SP2/0 mouse myeloma cells
- Antibodies were digested with trypsin, high-quality primary and secondary spectra were obtained through DNA data acquisition, and the spectra were de novo analyzed with peaks software to obtain preliminary amino acid sequence results; a variety of proteases were used to digest antibodies Solution, after MSE collects data, all peptide peaks and the completeness and fragmentation information of each valence state of each peptide can be obtained; the obtained more comprehensive mass spectrometry data is matched with the preliminary amino acid sequence, and finally two LIR1 singles are obtained.
- the amino acid sequences of chain antibodies are shown in Table 1 below.
- Opti-MEM 3ml Opti-MEM (Gibco, Item No. 31985-070) to a sterile tube to dilute the above plasmid, and then add the packaging vector psPAX2 (Addgene, Cat. No. 12260) and the envelope vector pMD2.G (Addgene, Cat. No. 12259). Then, add 120ul of X-treme GENE HP DNA transfection reagent (Roche, Cat. No. 06366236001), mix immediately, incubate at room temperature for 15 min, and then add the plasmid/vector/transfection reagent mixture dropwise to the culture flask of 293T cells . Viruses were collected at 24 hours and 48 hours, pooled, and ultracentrifuged (25000 g, 4°C, 2.5 hours) to obtain concentrated lentiviruses.
- T cells were activated with DynaBeads CD3/CD28 CTSTM (Gibco, Cat. No. 40203D) and cultured for 1 day at 37°C and 5% CO2. Then, the concentrated lentivirus was added, and after culturing for 3 days, T cells expressing the chimeric receptor containing the LIR1 antibody were obtained.
- DynaBeads CD3/CD28 CTSTM Gibco, Cat. No. 40203D
- the CRISPR/Cas9 system was then used to knock out TCR/CD3 components (specifically TRAC genes) and MHC-related genes ( Specifically, B2M and RFX5), Mock T cells, LIR1-UNKi-1-T cells (containing the LIR1-1 plasmid) and LIR1-UNKi-2-T cells (containing the LIR1-2 plasmid) were obtained, respectively. And using FITC Mouse Anti-Human CD3 (BD Pharmingen, Cat. No. 555916) antibody, PE mouse anti-human HLA-I (R&D Cat. No. FAB7098P) and APC anti-human DR, DP, DQ (biolegend, Cat. No. 361714) antibody, by flow The expression efficiency of CD3/HLA-I/HLA-II in UNKi-T cells, Mock T cells and NT cells was detected by cytometry, and the results are shown in Table 2 below.
- TRAC genes specifically, B2M and RFX5
- the UNKi-T cells and Mock-T cells prepared by the present invention were labeled with Far-Red (invitrogen, Cat. No. C34564).
- the labeled UNKi-T cells and Mock T cells were then plated into 96-well plates at a concentration of 1 ⁇ 10 4 cells/well, and NK92 cells were added at a 2:1 effector-target ratio for co-culture. After 16-18 hours, the proportion of T cells in the culture was detected by flow cytometry, and then the killing rate of NK cells to T cells was calculated. The results are shown in Figure 2.
- the two kinds of UNKi-T cells expressing the chimeric receptor containing LIR1 antibody prepared in this example can significantly reduce the killing effect of NK cells on T cells.
Abstract
The present invention provides an LIR1-targeted antibody, and a multi-specific antibody, chimeric receptor, antibody conjugate, pharmaceutical composition and kit comprising same, as well as use thereof in diagnosis/treatment/prevention of diseases associated with LIR1 expression.
Description
本发明属于免疫治疗领域。更具体地,本发明涉及靶向LIR1的抗体,及其在预防和/或治疗和/或诊断疾病中的用途。The present invention belongs to the field of immunotherapy. More specifically, the present invention relates to antibodies targeting LIR1 and their use in the prevention and/or treatment and/or diagnosis of diseases.
白细胞免疫球蛋白样受体(Leukocyte Immunoglobulin-like Receptor,LIR)也称为LILRB、免疫球蛋白样转录物(Immunoglobulin-like transcripts,ILT)或单核细胞-巨噬细胞抑制性受体(Monocyte-macrophage inhibitory receptor,MIR)。LIR一般包含2-4个胞外免疫球蛋白结构域、跨膜结构域和2-4个胞质免疫受体基于酪氨酸的抑制基序(ITIM)。LIR家族共有13个成员,其中LIR1能够结合抗原呈递细胞上的MHC I类分子,进而传导抑制信号以抑制免疫细胞的激活。据报道,LIR1在人胃癌细胞中表达,并且可增强肿瘤生长。此外,还发现LIR1可以控制炎症应答和细胞毒性,以有助于集中免疫应答并限制自身反应性。Leukocyte Immunoglobulin-like Receptor (LIR) is also known as LILRB, Immunoglobulin-like transcripts (ILT) or Monocyte-macrophage inhibitory receptor (Monocyte- macrophage inhibitory receptor, MIR). LIRs typically contain 2-4 extracellular immunoglobulin domains, transmembrane domains, and 2-4 cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). There are 13 members of the LIR family, of which LIR1 can bind to MHC class I molecules on antigen-presenting cells, thereby transducing inhibitory signals to inhibit the activation of immune cells. It has been reported that LIR1 is expressed in human gastric cancer cells and can enhance tumor growth. In addition, LIR1 was found to control inflammatory responses and cytotoxicity to help focus immune responses and limit autoreactivity.
本发明旨在提供一种靶向LIR1的抗体,及其在疾病预防和/或治疗和/或诊断中的用途。The present invention aims to provide an antibody targeting LIR1 and its use in disease prevention and/or treatment and/or diagnosis.
发明内容SUMMARY OF THE INVENTION
在第一个方面,本发明提供一种LIR1抗体,其包含:(1)如SEQ ID NO:1所示的CDR-L1、如SEQ ID NO:2所示的CDR-L2、如SEQ ID NO:3所示的CDR-L3、如SEQ ID NO:4所示的CDR-H1、如SEQ ID NO:5所示的CDR-H2、如SEQ ID NO:6所示的CDR-H3;或(2)如SEQ ID NO:10所示的CDR-L1、如SEQ ID NO:11所示的CDR-L2、如SEQ ID NO:12所示的CDR-L3、如SEQ ID NO:13 所示的CDR-H1、如SEQ ID NO:14所示的CDR-H2、如SEQ ID NO:15所示的CDR-H3。In a first aspect, the present invention provides a LIR1 antibody, comprising: (1) CDR-L1 as shown in SEQ ID NO: 1, CDR-L2 as shown in SEQ ID NO: 2, and CDR-L2 as shown in SEQ ID NO: 2 : CDR-L3 shown in 3, CDR-H1 shown in SEQ ID NO:4, CDR-H2 shown in SEQ ID NO:5, CDR-H3 shown in SEQ ID NO:6; or ( 2) CDR-L1 as shown in SEQ ID NO: 10, CDR-L2 as shown in SEQ ID NO: 11, CDR-L3 as shown in SEQ ID NO: 12, as shown in SEQ ID NO: 13 CDR-H1, CDR-H2 as shown in SEQ ID NO:14, CDR-H3 as shown in SEQ ID NO:15.
在一个实施方案中,所述LIR1抗体与选自SEQ ID NO:7和16所示的氨基酸序列具有至少90%同一性的轻链可变区,和与选自SEQ ID NO:8和17所示的氨基酸序列具有至少90%同一性的重链可变区。In one embodiment, the LIR1 antibody is at least 90% identical to a light chain variable region selected from the group consisting of amino acid sequences set forth in SEQ ID NOs: 7 and 16, and with a variable region selected from the group consisting of SEQ ID NOs: 8 and 17 The amino acid sequences shown have heavy chain variable regions that are at least 90% identical.
在一个实施方案中,所述LIR1抗体包含选自SEQ ID NO:7和16所示的轻链可变区和选自SEQ ID NO:8和17的重链可变区。在一个实施方案中,所述LIR1抗体包含如SEQ ID NO:7所示的轻链可变区和如SEQ ID NO:8所示的重链可变区;或如SEQ ID NO:16所示的轻链可变区和如SEQ ID NO:17所示的重链可变区。In one embodiment, the LIR1 antibody comprises a light chain variable region selected from the group consisting of SEQ ID NOs: 7 and 16 and a heavy chain variable region selected from the group consisting of SEQ ID NOs: 8 and 17. In one embodiment, the LIR1 antibody comprises a light chain variable region as set forth in SEQ ID NO:7 and a heavy chain variable region as set forth in SEQ ID NO:8; or as set forth in SEQ ID NO:16 The light chain variable region and the heavy chain variable region shown in SEQ ID NO: 17.
在一个实施方案中,所述LIR1抗体的氨基酸序列选自SEQ ID NO:9和18。In one embodiment, the amino acid sequence of the LIR1 antibody is selected from SEQ ID NOs: 9 and 18.
本发明还提供编码上述LIR1抗体的核酸分子。因此,在一个实施方案中,编码所述LIR1抗体的核酸分子与选自SEQ ID NO:19-20的核苷酸序列具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、100%序列同一性,并且其编码的LIR1抗体能够特异性结合LIR1抗原。优选地,编码所述LIR1抗体的核酸分子选自SEQ ID NO:19-20。The present invention also provides nucleic acid molecules encoding the above-mentioned LIR1 antibodies. Thus, in one embodiment, the nucleic acid molecule encoding the LIR1 antibody has at least 90%, 91%, 92%, 93%, 94%, 95% of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 19-20 , 96%, 97%, 98%, 99%, 100% sequence identity, and the LIR1 antibody encoded by it can specifically bind to the LIR1 antigen. Preferably, the nucleic acid molecule encoding the LIR1 antibody is selected from the group consisting of SEQ ID NOs: 19-20.
在另一个方面,本发明还提供一种多特异性抗体(优选双特异性抗体或三特异性抗体),其包含如上所述的LIR1抗体和一个或多个与其他抗原特异性结合的第二抗体或其抗原结合部分。In another aspect, the present invention also provides a multispecific antibody (preferably a bispecific or trispecific antibody) comprising the LIR1 antibody as described above and one or more second antibodies that specifically bind to other antigens An antibody or antigen-binding portion thereof.
在一个实施方案中,第二抗体或其抗原结合部分可以具有任何抗体或抗体片段形式,例如全长抗体、Fab、Fab'、(Fab')
2、Fv、scFv、scFv-scFv、微抗体、双抗体或sdAb。
In one embodiment, the second antibody or antigen-binding portion thereof may be in the form of any antibody or antibody fragment, such as a full-length antibody, Fab, Fab', (Fab') 2 , Fv, scFv, scFv-scFv, minibody, Diabodies or sdAbs.
本发明还提供包含编码上述LIR1抗体或多特异性抗体的核酸分子的载体,以及表达所述LIR1抗体或多特异性抗体的宿主细胞。The present invention also provides vectors comprising nucleic acid molecules encoding the above-mentioned LIR1 antibodies or multispecific antibodies, and host cells expressing the LIR1 antibodies or multispecific antibodies.
在另一个方面,本发明还提供一种嵌合受体,其包含一种或多种NK抑制性配体、跨膜结构域和信号传导结构域,其中所述NK抑 制性配体包含如上所述的LIR1抗体或含有所述LIR1抗体的多特异性抗体,其中所述信号传导结构域包含一个或多个共刺激结构域。In another aspect, the present invention also provides a chimeric receptor comprising one or more NK inhibitory ligands, a transmembrane domain and a signaling domain, wherein the NK inhibitory ligand comprises as described above The LIR1 antibody or a multispecific antibody comprising the LIR1 antibody, wherein the signaling domain comprises one or more costimulatory domains.
在一个实施方案中,所述嵌合受体包含两种NK抑制性配体,其中第一NK抑制性配体是如上所述的LIR1抗体,第二NK抑制性配体选自:(1)靶向以下NK抑制性受体的抗体或其片段:NKG2A、NKG2B、CD94、LIR2、LIR3、KIR2DL1、KIR2DL2/3、KIR3DL1、CEACAM1、LAIR1和KLRG1;或(2)HLA-E、HLA-F、HLA-G、钙黏素、胶原蛋白、OCIL、唾液酸、PD-L1、PD-L2、CD155、CD112、CD113、Gal-9、FGL1,和它们包含的NK抑制性受体结合区。In one embodiment, the chimeric receptor comprises two NK inhibitory ligands, wherein the first NK inhibitory ligand is a LIR1 antibody as described above and the second NK inhibitory ligand is selected from: (1) Antibodies or fragments thereof targeting the following NK inhibitory receptors: NKG2A, NKG2B, CD94, LIR2, LIR3, KIR2DL1, KIR2DL2/3, KIR3DL1, CEACAM1, LAIR1 and KLRG1; or (2) HLA-E, HLA-F, HLA-G, cadherin, collagen, OCIL, sialic acid, PD-L1, PD-L2, CD155, CD112, CD113, Gal-9, FGL1, and the NK inhibitory receptor binding domains they contain.
在一个实施方案中,本发明的嵌合受体中的所述信号传导结构域由一个或多个共刺激结构域组成。即,不包含初级信号传导结构域,例如来自FcRγ、FcRβ、CD3γ、CD3δ、CD3ε、CD3ζ、CD22、CD79a、CD79b和CD66d的初级信号传导结构域。In one embodiment, the signaling domain in a chimeric receptor of the invention consists of one or more costimulatory domains. That is, do not comprise primary signaling domains, eg, primary signaling domains from FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d.
在另一个实施方案中,本发明的嵌合受体的信号传导结构域还可以包含初级信号传导结构域,例如CD3ζ胞内区。In another embodiment, the signaling domain of the chimeric receptors of the invention may further comprise a primary signaling domain, eg, the CD3ζ intracellular region.
本发明还提供编码如上所定义的靶向LIR1的嵌合受体的核酸分子,以及包含所述核酸分子的载体。The present invention also provides nucleic acid molecules encoding a chimeric receptor targeting LIR1 as defined above, and vectors comprising said nucleic acid molecules.
本发明还提供一种工程化免疫细胞,其表达本发明的包含LIR1抗体的嵌合受体,并且其中至少一种MHC相关基因的表达被抑制或沉默。The present invention also provides an engineered immune cell expressing the chimeric receptor of the present invention comprising an LIR1 antibody, and wherein the expression of at least one MHC-related gene is inhibited or silenced.
在一个实施方案中,所述MHC相关基因选自:HLA-A、HLA-B、HLA-C、B2M、HLA-DPA、HLA-DQ、HLA-DRA、TAP1、TAP2、LMP2、LMP7、RFX5、RFXAP、RFXANK、CIITA和它们的组合,优选选自HLA-A、HLA-B、HLA-C、B2M、RFX5、RFXAP、RFXANK、CIITA和它们的组合。In one embodiment, the MHC-related genes are selected from the group consisting of: HLA-A, HLA-B, HLA-C, B2M, HLA-DPA, HLA-DQ, HLA-DRA, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, CIITA and combinations thereof are preferably selected from HLA-A, HLA-B, HLA-C, B2M, RFX5, RFXAP, RFXANK, CIITA and combinations thereof.
在一个实施方案中,所述表达本发明的包含LIR1抗体的嵌合受体的工程化免疫细胞进一步包括至少一种TCR/CD3基因的表达被抑制或沉默,所述TCR/CD3基因的实例包括例如TRAC、TRBC、CD3γ、CD3δ、CD3ε、CD3ζ。In one embodiment, the engineered immune cells expressing the chimeric receptor comprising the LIR1 antibody of the present invention further comprise that the expression of at least one TCR/CD3 gene is inhibited or silenced, examples of which include For example TRAC, TRBC, CD3γ, CD3δ, CD3ε, CD3ζ.
在一个实施方案中,本发明提供的工程化免疫细胞还表达靶向肿瘤抗原的嵌合抗原受体。In one embodiment, the engineered immune cells provided by the present invention further express chimeric antigen receptors targeting tumor antigens.
在一个实施方案中,所述免疫细胞选自T细胞、NK细胞、NKT细胞、巨噬细胞、树突细胞。In one embodiment, the immune cells are selected from T cells, NK cells, NKT cells, macrophages, dendritic cells.
在另一个方面,本发明还提供一种抗体偶联物,其包含本发明所定义的LIR1抗体和第二功能性结构,其中所述第二功能性结构选自Fc、放射性同位素、延长半衰期的结构部分、可检测标记物和药物。In another aspect, the present invention also provides an antibody conjugate comprising the LIR1 antibody as defined in the present invention and a second functional structure, wherein the second functional structure is selected from Fc, radioisotopes, half-life prolonging Structural moieties, detectable labels and drugs.
在一个实施方案中,所述延长半衰期的结构部分选自:所述延长半衰期的结构部分选自白蛋白的结合结构、转铁蛋白的结合结构、聚乙二醇分子、重组聚乙二醇分子、人血清白蛋白、人血清白蛋白的片段和结合人血清白蛋白的白多肽(包括抗体)。在一个实施方案中,可检测标记物选自荧光团、化学发光化合物、生物发光化合物、酶、抗生素抗性基因和造影剂。在一个实施方案中,所述药物选自细胞毒素和免疫调节剂。In one embodiment, the half-life extending moiety is selected from: the half-life extending moiety is selected from the binding structure of albumin, the binding structure of transferrin, polyethylene glycol molecules, recombinant polyethylene glycol molecules, Human serum albumin, fragments of human serum albumin, and albumin polypeptides (including antibodies) that bind human serum albumin. In one embodiment, the detectable label is selected from the group consisting of fluorophores, chemiluminescent compounds, bioluminescent compounds, enzymes, antibiotic resistance genes, and contrast agents. In one embodiment, the drug is selected from cytotoxins and immunomodulators.
在另一个方面,本发明还提供一种检测试剂盒,其包含本发明所述的抗体、多特异性抗体、抗体偶联物或嵌合受体。In another aspect, the present invention also provides a detection kit comprising the antibody, multispecific antibody, antibody conjugate or chimeric receptor of the present invention.
在另一个方面,本发明还提供一种药物组合物,其包含本发明所述的抗体、嵌合受体、多特异性抗体、工程化细胞或抗体偶联物,和一种或多种药学上可接受的赋形剂。In another aspect, the present invention also provides a pharmaceutical composition comprising the antibody, chimeric receptor, multispecific antibody, engineered cell or antibody conjugate of the present invention, and one or more pharmaceutical agents acceptable excipients.
在另一个方面,本发明还提供一种治疗和/或预防和/或诊断与LIR1表达相关的疾病的方法,包括向受试者施用如上所述的抗体、嵌合受体、多特异性抗体、抗体偶联物、工程化免疫细胞或药物组合物。In another aspect, the present invention also provides a method of treating and/or preventing and/or diagnosing a disease associated with LIR1 expression, comprising administering to a subject an antibody, chimeric receptor, multispecific antibody as described above , antibody conjugates, engineered immune cells or pharmaceutical compositions.
发明详述Detailed description of the invention
除非另有说明,否则本文中所使用的所有科学技术术语的含义与本发明所属领域的普通技术人员通常所了解的相同。Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
LIR1抗体Antibody to LIR1
如本文所用,术语“抗体”具有本领域技术人员所理解的最广泛的含义,并且包括单克隆抗体(包含完整抗体)、多克隆抗体、多价抗体、多特异性抗体(例如双特异性抗体)、和能够表现期望的生物活性的携带一个或多个CDR序列的抗体片段或合成多肽。本发明所述抗体可为任何种类(例如IgG、IgE、IgM、IgD、IgA等)或亚类(例如IgG1、IgG2、IgG2a、IgG3、IgG4、IgA1、IgA2等)。本发明的抗体也包含重组抗体、人抗体、人源化抗体、鼠源抗体、嵌合抗体及其抗原结合部分。As used herein, the term "antibody" has the broadest meaning as understood by those skilled in the art, and includes monoclonal antibodies (including whole antibodies), polyclonal antibodies, multivalent antibodies, multispecific antibodies (eg, bispecific antibodies) ), and antibody fragments or synthetic polypeptides carrying one or more CDR sequences capable of exhibiting the desired biological activity. The antibodies of the invention can be of any class (eg, IgG, IgE, IgM, IgD, IgA, etc.) or subclass (eg, IgGl, IgG2, IgG2a, IgG3, IgG4, IgAl, IgA2, etc.). Antibodies of the present invention also include recombinant antibodies, human antibodies, humanized antibodies, murine antibodies, chimeric antibodies, and antigen-binding portions thereof.
通常,完整抗体包括通过二硫键连接在一起的两条重链和两条轻链,每条轻链通过二硫键被连至各自的重链,呈“Y”形结构。每条重链包含重链可变区(VH)和重链恒定区,其中重链可变区包含三个互补决定区(CDR):CDR-H1、CDR-H2和CDR-H3,重链恒定区包含三个恒定结构域:CH1、CH2和CH3。每条轻链包含轻链可变区(VL)和轻链恒定区,其中轻链可变区包含三个CDR:CDR-L1、CDR-L2和CDR-L3,轻链恒定区包含一个恒定结构域CL。在重链/轻链可变区中,CDR被更保守的框架区(FR)隔开。重链/轻链的可变区负责与抗原的识别和结合,恒定区则可以介导抗体与宿主组织或因子的结合,包括免疫系统的各种细胞(例如效应细胞)和经典补体系统的第一组分。Typically, an intact antibody comprises two heavy chains and two light chains linked together by disulfide bonds, each light chain being disulfide bonded to its respective heavy chain in a "Y"-shaped structure. Each heavy chain comprises a heavy chain variable region (VH) and a heavy chain constant region, wherein the heavy chain variable region comprises three complementarity determining regions (CDRs): CDR-H1, CDR-H2 and CDR-H3, the heavy chain constant The region contains three constant domains: CH1, CH2 and CH3. Each light chain includes a light chain variable region (VL) and a light chain constant region, wherein the light chain variable region includes three CDRs: CDR-L1, CDR-L2 and CDR-L3, and the light chain constant region includes a constant structure Domain CL. In the heavy/light chain variable regions, the CDRs are separated by more conserved framework regions (FRs). The variable region of the heavy/light chain is responsible for antigen recognition and binding, while the constant region mediates the binding of antibodies to host tissues or factors, including various cells of the immune system (such as effector cells) and the first of the classical complement system. one component.
可以使用许多本领域熟知的编号方案容易地确定给定CDR或FR的精确氨基酸序列边界,这些方案包括:Kabat等人(1991),“Sequences ofProteins of Immunological Interest,”第5版Public Health Service,NationalInstitutes of Health,贝塞斯达,马里兰州(“Kabat”编号方案);Al-Lazikani等人,(1997)JMB273,927-948(“Chothia”编号方案);MacCallum等人,J.Mol.Biol.262:732-745(1996),“Antibody-antigen interactions:Contact analysis and binding sitetopography,”J.Mol.Biol.262,732-745”(“Contact”编号方案);Lefranc MP等人,“IMGTunique numbering for immunoglobulin and T cell receptor variable domains andIg superfamily V-like domains,”Dev Comp Immunol,2003年1月;27(1):55-77(“IMGT”编号方案);Honegger A和Plückthun A,“Yet another numbering scheme forimmunoglobulin variable domains:an automatic modeling and analysis tool,”JMol Biol,2001年6月8日;309(3):657-70(“Aho”编号方案);和Martin等人,“Modelingantibody hypervariable loops:a combined algorithm,”PNAS,1989,86(23):9268-9272(“AbM”编号方案)。The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using a number of numbering schemes well known in the art, including: Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th ed. Public Health Service, National Institutes of Health, Bethesda, Maryland ("Kabat" numbering scheme); Al-Lazikani et al, (1997) JMB273, 927-948 ("Chothia" numbering scheme); MacCallum et al, J.Mol.Biol. 262:732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding sitetopography," J. Mol. Biol. 262, 732-745" ("Contact" numbering scheme); Lefranc MP et al, "IMGTunique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol, 2003 Jan;27(1):55-77 (“IMGT” numbering scheme); Honegger A and Plückthun A, “Yet another numbering scheme forimmunoglobulin variable domains: an automatic modeling and analysis tool," JMol Biol, 2001 Jun 8;309(3):657-70 ("Aho" numbering scheme); and Martin et al, "Modelingantibody hypervariable loops: a combined algorithm," PNAS, 1989, 86(23):9268-9272 ("AbM" numbering scheme).
给定CDR或FR的边界可能取决于用于鉴定的方案而不同。例如,Kabat方案是基于结构比对,而Chothia方案是基于结构信息。Kabat和Chothia方案的编号都是基于最常见的抗体区域序列长度,其中通过插入字母提供插入(例如“30a”)并且在一些抗体中出现缺失。这两种方案将某些插入和缺失(“插入缺失(indel)”)放置在不同的位置,从而产生不同的编号。Contact方案是基于对复杂晶体结构的分析,并且在许多方面与Chothia编号方案相似。AbM方案是介于Kabat与Chothia定义之间的折衷,其基于Oxford Molecular的AbM抗体建模软件所使用的方案。The boundaries of a given CDR or FR may vary depending on the protocol used for identification. For example, the Kabat scheme is based on structural alignment, while the Chothia scheme is based on structural information. Both Kabat and Chothia's scheme numbering is based on the most common antibody region sequence lengths, where insertions are provided by intervening letters (eg "30a") and deletions occur in some antibodies. These two schemes place certain insertions and deletions ("indels") in different positions, resulting in different numbers. The Contact scheme is based on the analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme. The AbM protocol is a compromise between the Kabat and Chothia definitions and is based on the protocol used by Oxford Molecular's AbM antibody modeling software.
因此,除非另有规定,否则应当理解,给定抗体或其区域(如其可变区)的“CDR”涵盖由任何上述方案或其他已知方案所定义的CDR。例如,在指定特定的CDR(例如CDR3)含有给定氨基酸序列的情况下,应理解,这样的CDR还可以具有由任何上述方案或其他已知方案所定义的相应CDR(例如CDR3)的序列。同样,除非另有规定,否则应当理解给定抗体或其区域(如其可变区)的FR涵盖由任何上述方案或其他已知方案所定义的FR。Thus, unless otherwise specified, it should be understood that the "CDRs" of a given antibody or regions thereof (eg, variable regions thereof) encompass the CDRs defined by any of the above schemes or other known schemes. For example, where a particular CDR (eg, CDR3) is designated to contain a given amino acid sequence, it is to be understood that such CDR may also have the sequence of the corresponding CDR (eg, CDR3) as defined by any of the above or other known schemes. Likewise, unless otherwise specified, it should be understood that the FRs of a given antibody or region thereof (eg, variable regions thereof) encompass the FRs defined by any of the above schemes or other known schemes.
如本文所用,术语“抗体片段”或“抗原结合部分”仅包含完整抗体的一部分,一般包含完整抗体的抗原结合位点并因此保留结合抗原的能力。本发明中的抗体片段的实例包括但不限于:Fab、Fab'、F(ab')2、Fd片段、Fd′、Fv片段、scFv、二硫键-连接的Fv(sdFv)、抗体的重链可变区(VH)或轻链可变区(VL)、线性抗体、具有两个抗原结合位点的“双体”、单结构域抗体、纳米抗体、所述抗原 的天然配体或其功能性片段等。因此,本发明的“抗体”涵盖如上定义的抗体片段。As used herein, the term "antibody fragment" or "antigen-binding portion" encompasses only a portion of an intact antibody, typically comprising the antigen-binding site of the intact antibody and thus retaining the ability to bind antigen. Examples of antibody fragments in the present invention include, but are not limited to: Fab, Fab', F(ab')2, Fd fragment, Fd', Fv fragment, scFv, disulfide-linked Fv (sdFv), heavy Chain variable region (VH) or light chain variable region (VL), linear antibodies, "diabodies" with two antigen binding sites, single domain antibodies, nanobodies, natural ligands for said antigen or functional fragments, etc. Accordingly, "antibodies" of the present invention encompass antibody fragments as defined above.
在一个实施方案中,本发明的LIR1抗体是scFv。“单链抗体”和“scFv”在本文中可互换使用,是指由抗体重链可变区(VH)和轻链可变区(VL)通过接头连接而成的抗体。可以选择接头的最佳长度和/或氨基酸组成。接头的长度会明显影响scFv的可变区折叠和相互作用情况。事实上,如果使用较短的接头(例如在5-10个氨基酸之间),则可以防止链内折叠。关于接头的大小和组成的选择,参见例如,Hollinger等人,1993Proc Natl Acad.Sci.U.S.A.90:6444-6448;美国专利申请公布号2005/0100543、2005/0175606、2007/0014794;以及PCT公布号WO2006/020258和WO2007/024715,其全文通过引用并入本文。scFv可以包含以任何顺序连接的VH和VL,例如VH-接头-VL或VL-接头-VH。In one embodiment, the LIR1 antibody of the invention is an scFv. "Single-chain antibody" and "scFv" are used interchangeably herein and refer to an antibody comprising an antibody heavy chain variable region (VH) and light chain variable region (VL) linked by a linker. The optimal length and/or amino acid composition of the linker can be selected. The length of the linker significantly affects the variable region folding and interaction of scFv. In fact, intrachain folding can be prevented if shorter linkers are used (eg between 5-10 amino acids). For selection of linker size and composition, see, eg, Hollinger et al., 1993 Proc Natl Acad. Sci. U.S.A. 90:6444-6448; US Patent Application Publication Nos. 2005/0100543, 2005/0175606, 2007/0014794; WO2006/020258 and WO2007/024715, the entire contents of which are incorporated herein by reference. The scFv can comprise VH and VL linked in any order, eg, VH-linker-VL or VL-linker-VH.
在一个实施方案中,本发明的LIR1抗体包含(1)如SEQ ID NO:1所示的CDR-L1、如SEQ ID NO:2所示的CDR-L2、如SEQ ID NO:3所示的CDR-L3、如SEQ ID NO:4所示的CDR-H1、如SEQ ID NO:5所示的CDR-H2、如SEQ ID NO:6所示的CDR-H3;或(2)如SEQ ID NO:10所示的CDR-L1、如SEQ ID NO:11所示的CDR-L2、如SEQ ID NO:12所示的CDR-L3、如SEQ ID NO:13所示的CDR-H1、如SEQ ID NO:14所示的CDR-H2、如SEQ ID NO:15所示的CDR-H3。In one embodiment, the LIR1 antibody of the invention comprises (1) CDR-L1 as set forth in SEQ ID NO: 1, CDR-L2 as set forth in SEQ ID NO: 2, CDR-L2 as set forth in SEQ ID NO: 3 CDR-L3, CDR-H1 as set forth in SEQ ID NO:4, CDR-H2 as set forth in SEQ ID NO:5, CDR-H3 as set forth in SEQ ID NO:6; or (2) as SEQ ID NO:6 NO: CDR-L1 shown in SEQ ID NO: 10, CDR-L2 shown in SEQ ID NO: 11, CDR-L3 shown in SEQ ID NO: 12, CDR-H1 shown in SEQ ID NO: 13, CDR-H2 shown in SEQ ID NO: 14, CDR-H3 shown in SEQ ID NO: 15.
在一个实施方案中,所述LIR1抗体包含与选自SEQ ID NO:7和16的氨基酸序列具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、100%的序列同一性的轻链可变区,和与SEQ ID NO:8和17所示的氨基酸序列具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、100%的序列同一性的重链可变区。优选地,所述LIR1抗体包含选自SEQ ID NO:7和16所示的轻链可变区和选自SEQ ID NO:8和17所示的重链可变区。更优选地,所述LIR1抗体包含如SEQ ID NO:7所示的轻链可变区 和如SEQ ID NO:8所示的重链可变区;或如SEQ ID NO:16所示的轻链可变区和如SEQ ID NO:17所示的重链可变区。In one embodiment, the LIR1 antibody comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, A light chain variable region of 98%, 99%, 100% sequence identity, and having at least 90%, 91%, 92%, 93%, 94%, 90%, 91%, 92%, 93%, 94%, Heavy chain variable regions of 95%, 96%, 97%, 98%, 99%, 100% sequence identity. Preferably, the LIR1 antibody comprises a light chain variable region selected from the group consisting of SEQ ID NOs: 7 and 16 and a heavy chain variable region selected from the group consisting of SEQ ID NOs: 8 and 17. More preferably, the LIR1 antibody comprises a light chain variable region as shown in SEQ ID NO:7 and a heavy chain variable region as shown in SEQ ID NO:8; or a light chain as shown in SEQ ID NO:16 chain variable region and heavy chain variable region as set forth in SEQ ID NO:17.
在一个实施方案中,所述LIR1抗体的氨基酸序列如SEQ ID NO:9或18所示。In one embodiment, the amino acid sequence of the LIR1 antibody is set forth in SEQ ID NO: 9 or 18.
如本文所用,术语“序列同一性”表示两个(核苷酸或氨基酸)序列在比对中在相同位置处具有相同残基的程度,并且通常表示为百分数。优选地,同一性在被比较的序列的整体长度上确定。因此,具有完全相同序列的两个拷贝具有100%同一性。本领域技术人员知晓,可以使用一些算法来确定序列同一性,例如Blast(Altschul等(1997)Nucleic Acids Res.25:3389-3402)、Blast2(Altschul等(1990)J.Mol.Biol.215:403-410)、Smith-Waterman(Smith等(1981)J.Mol.Biol.147:195-197)和ClustalW。As used herein, the term "sequence identity" refers to the degree to which two (nucleotide or amino acid) sequences have identical residues at the same positions in an alignment, and is usually expressed as a percentage. Preferably, identity is determined over the entire length of the sequences being compared. Therefore, two copies with the exact same sequence are 100% identical. Those skilled in the art are aware that several algorithms can be used to determine sequence identity, such as Blast (Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402), Blast2 (Altschul et al. (1990) J. Mol. Biol. 215: 403-410), Smith-Waterman (Smith et al. (1981) J. Mol. Biol. 147: 195-197) and ClustalW.
在在一个方面,本发明还提供包含如上所述LIR1抗体的多特异性抗体(优选双特异性抗体或三特异性抗体),其还包含一个或多个与其他抗原特异性结合的第二抗体。In one aspect, the present invention also provides a multispecific antibody (preferably a bispecific or trispecific antibody) comprising the LIR1 antibody as described above, which further comprises one or more secondary antibodies that specifically bind to other antigens .
如本文所用,术语“多特异性”是指抗原结合蛋白具有多表位特异性(即,能够特异性结合一个生物分子上的两个、三个或更多个不同的表位或能够特异性结合两个、三个或更多个不同的生物分子上的表位)。如本文所用,术语“双特异性”表示抗原结合蛋白具有两种不同的抗原结合特异性。As used herein, the term "multispecific" refers to an antigen binding protein that has polyepitopic specificity (ie, is capable of specifically binding to two, three or more different epitopes on a biomolecule or capable of specific binds epitopes on two, three or more different biomolecules). As used herein, the term "bispecific" means that an antigen binding protein has two different antigen binding specificities.
在一个实施方案中,第二抗体可以具有任何抗体或抗体片段形式,例如全长抗体、Fab、Fab'、(Fab')
2、Fv、scFv、scFv-scFv、微抗体、双抗体或sdAb。
In one embodiment, the secondary antibody may be in any antibody or antibody fragment format, eg, a full-length antibody, Fab, Fab', (Fab') 2 , Fv, scFv, scFv-scFv, minibody, diabody, or sdAb.
核酸、载体、宿主细胞Nucleic acids, vectors, host cells
在另一方面中,本发明涉及编码本发明的LIR1抗体或多特异性抗体的核酸分子。本发明的核酸可为RNA、DNA或cDNA。根据本发明的一个实施方案,本发明的核酸是基本上分离的核酸。In another aspect, the invention relates to nucleic acid molecules encoding the LIR1 antibodies or multispecific antibodies of the invention. The nucleic acid of the present invention may be RNA, DNA or cDNA. According to one embodiment of the invention, the nucleic acid of the invention is a substantially isolated nucleic acid.
在一个实施方案中,编码所述LIR1抗体的核酸分子与选自SEQ ID NO:19-20的核苷酸序列具有至少90%、91%、92%、93%、94%、 95%、96%、97%、98%、99%、100%序列同一性,并且其编码的LIR1抗体能够特异性结合LIR1抗原。优选地,编码所述LIR1抗体的核酸分子如SEQ ID NO:19-20所示。In one embodiment, the nucleic acid molecule encoding the LIR1 antibody has at least 90%, 91%, 92%, 93%, 94%, 95%, 96% of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 19-20 %, 97%, 98%, 99%, 100% sequence identity, and the LIR1 antibody encoded by it can specifically bind to LIR1 antigen. Preferably, the nucleic acid molecules encoding the LIR1 antibodies are shown in SEQ ID NOs: 19-20.
本发明的核酸也可呈载体形式,可存在于载体中和/或可为载体的一部分,该载体例如质粒、粘端质粒或YAC。载体可尤其为表达载体,即可提供LIR1抗体在体外和/或体内(即在适合宿主细胞、宿主有机体和/或表达系统中)表达的载体。该表达载体通常包含至少一种本发明的核酸分子,其可操作地连接至一个或多个适合的表达调控元件(例如启动子、增强子、终止子等)。对所述调控元件及其序列进行选择以便在特定宿主中表达是本领域技术人员熟知的。对本发明的LIR1抗体的表达有用或必需的调控元件及其他元件的具体实例包括但不限于启动子、增强子、终止子、整合因子、选择标记物、前导序列、报告基因。The nucleic acid of the present invention may also be in the form of, may be present in and/or be part of a vector, such as a plasmid, cosmid or YAC. The vector may in particular be an expression vector, ie a vector that provides for expression of the LIR1 antibody in vitro and/or in vivo (ie in a suitable host cell, host organism and/or expression system). The expression vector typically comprises at least one nucleic acid molecule of the invention operably linked to one or more suitable expression control elements (eg, promoters, enhancers, terminators, etc.). Selection of such regulatory elements and their sequences for expression in a particular host is well known to those skilled in the art. Specific examples of regulatory elements and other elements useful or necessary for the expression of the LIR1 antibodies of the invention include, but are not limited to, promoters, enhancers, terminators, integration factors, selectable markers, leader sequences, reporter genes.
在另一方面中,本发明还提供表达本发明的LIR1抗体、多特异性抗体和/或含有本发明的核酸或载体的宿主细胞。本发明的优选宿主细胞为细菌细胞、真菌细胞或哺乳动物细胞。In another aspect, the present invention also provides host cells expressing the LIR1 antibodies, multispecific antibodies of the present invention and/or containing the nucleic acids or vectors of the present invention. Preferred host cells of the present invention are bacterial cells, fungal cells or mammalian cells.
适合的细菌细胞包括革兰氏阴性细菌菌株(例如大肠杆菌(Escherichia coli)菌株、变形杆菌属(Proteus)菌株及假单胞菌属(Pseudomonas)菌株)及革兰氏阳性细菌菌株(例如芽孢杆菌属(Bacillus)菌株、链霉菌属(Streptomyces)菌株、葡萄球菌属(Staphylococcus)菌株及乳球菌属(Lactococcus)菌株)的细胞。Suitable bacterial cells include gram-negative bacterial strains (eg, Escherichia coli, Proteus, and Pseudomonas strains) and gram-positive bacterial strains (eg, Bacillus Bacillus strains, Streptomyces strains, Staphylococcus strains and Lactococcus strains).
适合的真菌细胞包括木霉属(Trichoderma)、脉孢菌属(Neurospora)及曲菌属(Aspergillus)的物种的细胞;或者包括酵母属(Saccharomyces)(例如酿酒酵母(Saccharomyces cerevisiae))、裂殖酵母属(Schizosaccharomyces)(例如粟酒裂殖酵母(Schizosaccharomyces pombe))、毕赤酵母属(Pichia)(例如巴斯德毕赤酵母(Pichiapastoris)及嗜甲醇毕赤酵母(Pichia methanolica))及汉森酵母属(Hansenula)的物种的细胞。Suitable fungal cells include cells of species of Trichoderma, Neurospora and Aspergillus; or Saccharomyces (eg Saccharomyces cerevisiae), Saccharomyces (such as Schizosaccharomyces pombe), Pichia (such as Pichia pastoris and Pichia methanolica) and Hansen A cell of a species of the genus Hansenula.
适合的哺乳动物细胞包括例如HEK293细胞、CHO细胞、BHK 细胞、HeLa细胞、COS细胞等。Suitable mammalian cells include, for example, HEK293 cells, CHO cells, BHK cells, HeLa cells, COS cells, and the like.
然而,本发明也可使用两栖类细胞、昆虫细胞、植物细胞及本领域中用于表达异源蛋白的任何其他细胞。However, amphibian cells, insect cells, plant cells, and any other cell in the art for expressing heterologous proteins may also be used in the present invention.
嵌合受体chimeric receptor
在另一方面,本发明还提供包含如上所述的LIR1抗体的嵌合受体。由于LIR1是一种NK抑制性受体,因此包含LIR1抗体的嵌合受体可以用于抑制NK细胞的杀伤作用。In another aspect, the present invention also provides a chimeric receptor comprising the LIR1 antibody as described above. Since LIR1 is an NK inhibitory receptor, chimeric receptors comprising LIR1 antibodies can be used to inhibit the killing of NK cells.
在一个实施方案中,本发明提供一种嵌合受体,其包含一种或多种NK抑制性配体、跨膜结构域和信号传导结构域,其中所述NK抑制性配体包含如上所述的LIR1抗体或含有所述LIR1抗体的多特异性抗体,其中所述信号传导结构域包含一个或多个共刺激结构域。In one embodiment, the present invention provides a chimeric receptor comprising one or more NK inhibitory ligands, a transmembrane domain, and a signaling domain, wherein the NK inhibitory ligand comprises as described above The LIR1 antibody or a multispecific antibody comprising the LIR1 antibody, wherein the signaling domain comprises one or more costimulatory domains.
在一个实施方案中,所述嵌合受体包含多种NK抑制性配体,例如两种NK抑制性配体,其中第一NK抑制性配体是如上所述的LIR1抗体,第二NK抑制性配体是靶向其他NK抑制性受体的抗体或其片段,和/或其他NK抑制性受体的天然配体或其包含的NK抑制性受体结合区。In one embodiment, the chimeric receptor comprises multiple NK inhibitory ligands, eg, two NK inhibitory ligands, wherein the first NK inhibitory ligand is a LIR1 antibody as described above and the second NK inhibitory ligand Sexual ligands are antibodies or fragments thereof that target other NK inhibitory receptors, and/or natural ligands for other NK inhibitory receptors or NK inhibitory receptor binding regions they comprise.
在一个实施方案中,所述第二NK抑制性配体是选自靶向以下NK抑制性受体的抗体或其片段:NKG2/CD94组分(例如NKG2A、NKG2B、CD94);杀伤细胞Ig样受体(KIR)家族成员(例如KIR2DL1、KIR2DL2/3、KIR2DL5A、KIR2DL5B、KIR3DL1、KIR3DL2和KIR3DL3);白细胞Ig样受体(LIR)家族成员(例如LIR2、LIR3、LIR5和LIR8);NK细胞受体蛋白1(NKR-P1)家族成员(例如NKR-P1B和NKR-P1D);免疫检查点受体(例如PD-1、TIGIT和CD96、TIM3、LAG3);癌胚抗原相关的细胞黏附分子1(CEACAM1);唾液酸结合性免疫球蛋白样凝集素(SIGLEC)家族成员(例如SIGLEC7和SIGLEC9);白细胞相关的免疫球蛋白样受体1(LAIR1);Ly49家族成员(例如Ly49A、Ly49C、Ly49F、Ly49G1和Ly49G4)和杀伤细胞凝集素样受体G1(KLRG1)。更优选地,所述第二NK抑制性配体选自靶向以下NK抑制性受体的抗体或其片段:NKG2A、NKG2B、 CD94、LIR2、LIR3、KIR2DL1、KIR2DL2/3、KIR3DL1、CEACAM1、LAIR1和KLRG1。还更优选地,所述第二NK抑制性配体选自靶向以下NK抑制性受体的抗体或其片段:NKG2A、CD94、KIR2DL1、KIR2DL2/3、KIR3DL1、CEACAM1、LAIR1和KLRG1。In one embodiment, the second NK inhibitory ligand is an antibody or fragment thereof that targets the following NK inhibitory receptors: NKG2/CD94 components (eg, NKG2A, NKG2B, CD94); Killer cell Ig-like Receptor (KIR) family members (eg, KIR2DL1, KIR2DL2/3, KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL2, and KIR3DL3); leukocyte Ig-like receptor (LIR) family members (eg, LIR2, LIR3, LIR5, and LIR8); NK cells are affected by Body protein 1 (NKR-P1) family members (eg, NKR-P1B and NKR-P1D); immune checkpoint receptors (eg, PD-1, TIGIT and CD96, TIM3, LAG3); carcinoembryonic antigen-associated cell adhesion molecule 1 (CEACAM1); sialic acid-binding immunoglobulin-like lectin (SIGLEC) family members (eg, SIGLEC7 and SIGLEC9); leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Ly49 family members (eg, Ly49A, Ly49C, Ly49F) , Ly49G1 and Ly49G4) and killer lectin-like receptor G1 (KLRG1). More preferably, the second NK inhibitory ligand is selected from antibodies or fragments thereof targeting the following NK inhibitory receptors: NKG2A, NKG2B, CD94, LIR2, LIR3, KIR2DL1, KIR2DL2/3, KIR3DL1, CEACAM1, LAIR1 and KLRG1. Still more preferably, the second NK inhibitory ligand is selected from the group consisting of antibodies or fragments thereof targeting the following NK inhibitory receptors: NKG2A, CD94, KIR2DL1, KIR2DL2/3, KIR3DL1, CEACAM1, LAIR1 and KLRG1.
在一个实施方案中,所述第二NK抑制性配体是其他NK抑制性受体的天然配体或其包含的NK抑制性受体结合区,例如HLA-E、HLA-F、HLA-G、钙黏素、胶原蛋白、OCIL、唾液酸、免疫检查点配体(例如PD-L1/PD-L2、CD155、CD112、CD113、Gal-9、FGL1等),和它们包含的NK抑制性受体结合区。优选地,所述第二NK抑制性配体选自HLA-E、HLA-F、HLA-G、钙黏素、PD-L1、PD-L2,或它们包含的NK抑制性受体结合区。更优选的,所述第二NK抑制性配体选自HLA-E胞外区、HLA-G胞外区、E-钙黏素胞外区、PD-L1胞外区和PD-L2胞外区。更优选的,所述第二NK抑制性配体是E-钙黏素胞外区,其包含EC1和EC2,更优选包含EC1、EC2、EC3、EC4和EC5。In one embodiment, the second NK inhibitory ligand is a natural ligand of another NK inhibitory receptor or the NK inhibitory receptor binding region it comprises, eg, HLA-E, HLA-F, HLA-G , cadherin, collagen, OCIL, sialic acid, immune checkpoint ligands (eg PD-L1/PD-L2, CD155, CD112, CD113, Gal-9, FGL1, etc.), and the NK inhibitory receptors they contain body binding region. Preferably, the second NK inhibitory ligand is selected from HLA-E, HLA-F, HLA-G, cadherin, PD-L1, PD-L2, or the NK inhibitory receptor binding regions they comprise. More preferably, the second NK inhibitory ligand is selected from HLA-E extracellular domain, HLA-G extracellular domain, E-cadherin extracellular domain, PD-L1 extracellular domain and PD-L2 extracellular domain Area. More preferably, the second NK inhibitory ligand is the E-cadherin extracellular domain comprising EC1 and EC2, more preferably EC1, EC2, EC3, EC4 and EC5.
如本文所用,术语“跨膜结构域”是指能够使嵌合受体在免疫细胞(例如淋巴细胞、NK细胞或NKT细胞)表面上表达,并且引导免疫细胞针对靶细胞的细胞应答的多肽结构。跨膜结构域可以是天然或合成的,也可以源自任何膜结合蛋白或跨膜蛋白。当嵌合受体与靶抗原结合时,跨膜结构域能够进行信号传导。特别适用于本发明中的跨膜结构域可以源自例如TCRα链、TCRβ链、TCRγ链、TCRδ链、CD3ζ亚基、CD3ε亚基、CD3γ亚基、CD3δ亚基、CD45、CD4、CD5、CD8α、CD9、CD16、CD22、CD33、CD28、CD37、CD64、CD80、CD86、CD134、CD137、CD154及其功能性片段。或者,跨膜结构域可以是合成的并且可以主要地包含疏水性残基如亮氨酸和缬氨酸。优选地,所述跨膜结构域源自CD8α链或CD28,其与SEQ ID NO:24或26所示的氨基酸序列具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性,或其编码序列与SEQ ID NO:25或27所示的核酸分子具有至少 70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性。As used herein, the term "transmembrane domain" refers to a polypeptide structure that enables expression of a chimeric receptor on the surface of immune cells (eg, lymphocytes, NK cells, or NKT cells) and directs the cellular response of the immune cells against target cells . The transmembrane domain can be natural or synthetic, and can be derived from any membrane-bound or transmembrane protein. The transmembrane domain is capable of signaling when the chimeric receptor binds to the target antigen. Transmembrane domains particularly useful in the present invention may be derived from, for example, TCRα chain, TCRβ chain, TCRγ chain, TCRδ chain, CD3ζ subunit, CD3ε subunit, CD3γ subunit, CD3δ subunit, CD45, CD4, CD5, CD8α , CD9, CD16, CD22, CD33, CD28, CD37, CD64, CD80, CD86, CD134, CD137, CD154 and their functional fragments. Alternatively, the transmembrane domain may be synthetic and may contain predominantly hydrophobic residues such as leucine and valine. Preferably, the transmembrane domain is derived from the CD8 alpha chain or CD28, which is at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% of the amino acid sequence shown in SEQ ID NO: 24 or 26 % or 99% or 100% sequence identity, or its coding sequence has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% with the nucleic acid molecule shown in SEQ ID NO: 25 or 27 or 99% or 100% sequence identity.
如本文所用,术语“共刺激结构域”是指来自共刺激分子的细胞内功能性信号传导结构域,其包含所述共刺激分子的整个细胞内部分,或其功能片段。“共刺激分子”是指在T细胞上与共刺激配体特异性结合,由此介导T细胞的共刺激反应(例如增殖)的同源结合配偶体。共刺激分子包括但不限于1类MHC分子、BTLA和Toll配体受体。本发明的共刺激结构域的非限制性施例包括但不限于源自以下蛋白质的胞内区:TLR1、TLR2、TLR3、TLR4、TLR5、TLR6、TLR7、TLR8、TLR9、TLR10、CARD11、CD2、CD7、CD8、CD18(LFA-1)、CD27、CD28、CD30、CD40、CD54(ICAM)、CD83、CD134(OX40)、CD137(4-1BB)、CD270(HVEM)、CD272(BTLA)、CD276(B7-H3)、CD278(ICOS)、CD357(GITR)、DAP10、LAT、NKG2C、SLP76、PD-1、LIGHT、TRIM以及ZAP70。优选地,本发明CAR的共刺激结构域来自4-1BB、CD28或4-1BB+CD28。在一个实施方案中,4-1BB共刺激结构域与SEQ ID NO:27所示的氨基酸序列具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性,或其编码序列与SEQ ID NO:28所示的核酸分子具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性。在一个实施方案中,CD28共刺激结构域与SEQ ID NO:25所示的氨基酸序列具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性,或其编码序列与SEQ ID NO:26所示的核酸分子具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性。As used herein, the term "costimulatory domain" refers to an intracellular functional signaling domain from a costimulatory molecule that comprises the entire intracellular portion of the costimulatory molecule, or a functional fragment thereof. A "costimulatory molecule" refers to a cognate binding partner that specifically binds to a costimulatory ligand on a T cell, thereby mediating a costimulatory response (eg, proliferation) of the T cell. Costimulatory molecules include, but are not limited to, MHC class 1 molecules, BTLA and Toll ligand receptors. Non-limiting examples of costimulatory domains of the invention include, but are not limited to, intracellular regions derived from the following proteins: TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD8, CD18 (LFA-1), CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40), CD137 (4-1BB), CD270 (HVEM), CD272 (BTLA), CD276 ( B7-H3), CD278 (ICOS), CD357 (GITR), DAP10, LAT, NKG2C, SLP76, PD-1, LIGHT, TRIM and ZAP70. Preferably, the costimulatory domain of the CAR of the present invention is from 4-1BB, CD28 or 4-1BB+CD28. In one embodiment, the 4-1BB costimulatory domain is at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% of the amino acid sequence set forth in SEQ ID NO:27 % sequence identity, or its coding sequence has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence with the nucleic acid molecule shown in SEQ ID NO: 28 identity. In one embodiment, the CD28 costimulatory domain has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% of the amino acid sequence set forth in SEQ ID NO:25 Sequence identity, or its coding sequence, has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the nucleic acid molecule set forth in SEQ ID NO:26 .
在一个实施方案中,所述信号传导结构域由一个或多个共刺激结构域组成(即,不包含初级信号传导结构域,例如来自FcRγ、FcRβ、CD3γ、CD3δ、CD3ε、CD3ζ、CD22、CD79a、CD79b和CD66d的初级信号传导结构域)。在另一个实施方案中,本发明 的嵌合受体的信号传导结构域还可以包含初级信号传导结构域,例如CD3ζ胞内区。在优选的实施方式中,所述CD3ζ胞内区与SEQ ID NO:29或31所示的氨基酸序列具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性,或其编码序列与SEQ ID NO:30或32所示的核酸分子具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性。In one embodiment, the signaling domain consists of one or more costimulatory domains (ie, does not comprise a primary signaling domain, eg, from FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a , the primary signaling domains of CD79b and CD66d). In another embodiment, the signaling domain of a chimeric receptor of the invention may also comprise a primary signaling domain, such as the CD3ζ intracellular region. In a preferred embodiment, the CD3ζ intracellular region is at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% of the amino acid sequence shown in SEQ ID NO: 29 or 31 or 100% sequence identity, or its coding sequence has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% with the nucleic acid molecule shown in SEQ ID NO: 30 or 32 or 100% sequence identity.
在一个实施方案中,本发明的嵌合受体还可以包含位于抗体和跨膜结构域之间的铰链区。如本文所用,术语“铰链区”一般是指作用为连接跨膜结构域和抗体的任何寡肽或多肽。具体地,铰链区用来为配体结合结构域提供更大的灵活性和可及性。铰链区可以包含最多达300个氨基酸,优选10至100个氨基酸并且最优选25至50个氨基酸。铰链区可以全部或部分源自天然分子,如全部或部分源自CD8、CD4或CD28的胞外区,或全部或部分源自抗体恒定区。或者,铰链区可以是对应于天然存在的铰链序列的合成序列,或可以是完全合成的铰链序列。在优选的实施方式中,所述铰链区包含CD8α、CD28、FcγRIIIα受体、IgG4或IgG1的铰链区部分,更优选CD8α、CD28或IgG4铰链,其与SEQ ID NO:37、39或41所示的氨基酸序列具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性,或其编码序列与SEQ ID NO:38、40或42所示的核苷酸序列具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性。In one embodiment, the chimeric receptors of the invention may further comprise a hinge region between the antibody and the transmembrane domain. As used herein, the term "hinge region" generally refers to any oligopeptide or polypeptide that functions to link a transmembrane domain and an antibody. Specifically, the hinge region serves to provide greater flexibility and accessibility to the ligand binding domain. The hinge region may comprise up to 300 amino acids, preferably 10 to 100 amino acids and most preferably 25 to 50 amino acids. The hinge region can be derived in whole or in part from a native molecule, such as in whole or in part from the extracellular region of CD8, CD4 or CD28, or in whole or in part from an antibody constant region. Alternatively, the hinge region may be a synthetic sequence corresponding to a naturally occurring hinge sequence, or may be a fully synthetic hinge sequence. In a preferred embodiment, the hinge region comprises a CD8α, CD28, FcγRIIIα receptor, IgG4 or IgG1 hinge region portion, more preferably a CD8α, CD28 or IgG4 hinge, which is set forth in SEQ ID NO: 37, 39 or 41 The amino acid sequence has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity, or its coding sequence is identical to that of SEQ ID NO: 38, 40 or 42 The nucleotide sequences shown have at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity.
在一个实施方案中,本发明的CR还可以包含信号肽,使得当其在细胞例如T细胞中表达时,新生蛋白质被引导至内质网并随后引导至细胞表面。信号肽的核心可以含有长的疏水性氨基酸区段,其具有形成单个α-螺旋的倾向。在信号肽的末端,通常有被信号肽酶识别和切割的氨基酸区段。信号肽酶可以在移位期间或完成后切割,以产生游离信号肽和成熟蛋白。然后,游离信号肽被特定蛋白酶消化。可用于本发明的信号肽是本领域技术人员熟知的,例如衍生自 B2M、CD8α、IgG1、GM-CSFRα等的信号肽。在一个实施方案中,可用于本发明的信号肽来自B2M或CD8α,其与SEQ ID NO:33或35所示的氨基酸序列具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性,或其编码序列与SEQ ID NO:34或36所示的核酸分子具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性。In one embodiment, the CR of the invention may also comprise a signal peptide such that when expressed in a cell, eg, a T cell, the nascent protein is directed to the endoplasmic reticulum and subsequently to the cell surface. The core of the signal peptide may contain a long segment of hydrophobic amino acids that has a tendency to form a single alpha-helix. At the end of the signal peptide, there is usually a segment of amino acids that is recognized and cleaved by signal peptidases. The signal peptidase can cleave during or after translocation to generate the free signal peptide and mature protein. Then, the free signal peptide is digested by specific proteases. Signal peptides useful in the present invention are well known to those skilled in the art, for example signal peptides derived from B2M, CD8α, IgG1, GM-CSFRα, and the like. In one embodiment, the signal peptide useful in the present invention is from B2M or CD8α, which is at least 70%, preferably at least 80%, more preferably at least 90%, 95% of the amino acid sequence shown in SEQ ID NO: 33 or 35 , 97% or 99% or 100% sequence identity, or its coding sequence has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity.
在一个实施方案中,所述CR含有如本文所提供的LIR1抗体或含有所述LIR1抗体的多特异性抗体、CD8α跨膜区和信号传导结构域,所述信号传导结构域包含选自CD28和4-1BB的共刺激结构域。优选地,所述信号传导结构域由选自CD28和4-1BB的共刺激结构域组成。在另一个实施方案中,所述信号传导结构域还包含CD3ζ胞内区。在该实施方案中,所述CAR还可以进一步包含来自B2M、CD8α、IgG1或GM-CSFRα的信号肽。In one embodiment, the CR comprises a LIR1 antibody as provided herein or a multispecific antibody comprising the LIR1 antibody, a CD8α transmembrane region, and a signaling domain comprising the group consisting of CD28 and The costimulatory domain of 4-1BB. Preferably, the signaling domain consists of a costimulatory domain selected from CD28 and 4-1BB. In another embodiment, the signaling domain further comprises the CD3ζ intracellular domain. In this embodiment, the CAR may further comprise a signal peptide from B2M, CD8α, IgG1 or GM-CSFRα.
本发明还提供编码如上所定义的靶向LIR1的嵌合受体的核酸分子,以及包含所述核酸分子的载体。The present invention also provides nucleic acid molecules encoding a chimeric receptor targeting LIR1 as defined above, and vectors comprising said nucleic acid molecules.
如本文所用,术语“载体”是用作将(外源)遗传材料转移到宿主细胞中的媒介核酸分子,在该宿主细胞中所述核酸分子可以例如复制和/或表达。载体一般包括靶向载体和表达载体。“靶向载体”是通过例如同源重组或使用特异性靶向位点处序列的杂合重组酶将分离的核酸递送至细胞内部的介质。“表达载体”是用于异源核酸序列(例如编码本发明的嵌合受体多肽的那些序列)在合适的宿主细胞中的转录以及它们的mRNA的翻译的载体。可用于本发明的合适载体是本领域已知的,并且许多可商购获得。在一个实施方案中,本发明的载体包括但不限于质粒、病毒(例如逆转录病毒、慢病毒、腺病毒、牛痘病毒、劳氏肉瘤病毒(RSV、多瘤病毒和腺相关病毒(AAV)等)、噬菌体、噬菌粒、粘粒和人工染色体(包括BAC和YAC)。载体本身通常是核酸分子,通常是包含插入物(转基因)的DNA序列和作为载体“骨架”的较大序列。工程化载体通常还包含在宿主细胞中自主复制的起点(如果需要多核苷酸的稳定表达)、选择标记和限制酶 切割位点(如多克隆位点,MCS)。载体可另外包含启动子、多聚腺苷酸尾(polyA)、3’UTR、增强子、终止子、绝缘子、操纵子、选择标记、报告基因、靶向序列和/或蛋白质纯化标签等元件。在一个具体的实施方案中,所述载体是体外转录的载体。As used herein, the term "vector" is a nucleic acid molecule used as a vehicle for the transfer of (exogenous) genetic material into a host cell, in which the nucleic acid molecule can eg be replicated and/or expressed. Vectors generally include targeting vectors and expression vectors. A "targeting vector" is a medium that delivers an isolated nucleic acid to the interior of a cell by, for example, homologous recombination or a hybrid recombinase using a specific targeting sequence at the site. An "expression vector" is a vector used for the transcription of heterologous nucleic acid sequences, such as those encoding the chimeric receptor polypeptides of the invention, in suitable host cells, and the translation of their mRNAs. Suitable carriers for use in the present invention are known in the art and many are commercially available. In one embodiment, the vectors of the present invention include, but are not limited to, plasmids, viruses (eg, retroviruses, lentiviruses, adenoviruses, vaccinia virus, Rous sarcoma virus (RSV, polyoma virus, and adeno-associated virus (AAV)), and the like ), phages, phagemids, cosmids, and artificial chromosomes (including BACs and YACs). The vector itself is usually a nucleic acid molecule, usually a DNA sequence containing an insert (transgene) and a larger sequence that serves as the "backbone" of the vector. Engineering The VL vector typically also contains an origin of autonomous replication in the host cell (if stable expression of the polynucleotide is desired), a selectable marker, and a restriction enzyme cleavage site (eg, a multiple cloning site, MCS). The vector may additionally contain a promoter, multiple elements such as polyadenylated tails (polyA), 3'UTRs, enhancers, terminators, insulators, operons, selectable markers, reporter genes, targeting sequences and/or protein purification tags. In a specific embodiment, The vector is an in vitro transcribed vector.
工程化免疫细胞engineered immune cells
由于LIR1能够与HLA-I类分子结合,进而抑制免疫细胞例如NK细胞的激活。因此引入外源性的LIR1抗体能够通过结合LIR1来实现抑制NK细胞杀伤作用的效果,这在某些情况下(例如HLA-I类分子缺失或制备通用型CAR-T细胞的情况下)尤其有用。Since LIR1 can bind to HLA-I molecules, it inhibits the activation of immune cells such as NK cells. Therefore, the introduction of exogenous LIR1 antibodies can inhibit the killing effect of NK cells by binding to LIR1, which is especially useful in certain situations (such as the deletion of HLA-I molecules or the preparation of universal CAR-T cells). .
因此在一个方面,本发明还提供一种工程化免疫细胞,其表达本发明的包含LIR1抗体的嵌合受体,并且其中至少一种MHC相关基因的表达被抑制或沉默。Accordingly, in one aspect, the present invention also provides an engineered immune cell expressing a chimeric receptor of the present invention comprising a LIR1 antibody, and wherein the expression of at least one MHC-related gene is inhibited or silenced.
如本文所用,MHC相关基因包括MHC基因本身(例如,MHC-I类分子和MHC-II类分子),以及与MHC基因相互作用或调控其表达的基因。MHC-I类分子的实例包括但不限于HLA-A、HLA-B、HLA-C、B2M。MHC-II类分子的实例包括但不限于HLA-DPA1、HLA-DQA1和HLA-DRA。与MHC基因相互作用或调控其表达的基因的实例包括但不限于TAP1、TAP2、LMP2、LMP7、RFX5、RFXAP、RFXANK和CIITA。As used herein, MHC-related genes include MHC genes themselves (eg, MHC-class I molecules and MHC-class II molecules), as well as genes that interact with or regulate expression of MHC genes. Examples of MHC-class I molecules include, but are not limited to, HLA-A, HLA-B, HLA-C, B2M. Examples of MHC-class II molecules include, but are not limited to, HLA-DPAl, HLA-DQA1, and HLA-DRA. Examples of genes that interact with or regulate expression of MHC genes include, but are not limited to, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, and CIITA.
因此,在一个实施方案中,使MHC相关基因的表达被抑制或沉默是指使选自以下的一个或多个基因的表达被抑制或沉默:HLA-A、HLA-B、HLA-C、B2M、HLA-DPA、HLA-DQ、HLA-DRA、TAP1、TAP2、LMP2、LMP7、RFX5、RFXAP、RFXANK、CIITA和它们的组合,优选选自HLA-A、HLA-B、HLA-C、B2M、RFX5、RFXAP、RFXANK、CIITA和它们的组合。Thus, in one embodiment, suppressing or silencing the expression of MHC-related genes refers to suppressing or silencing the expression of one or more genes selected from the group consisting of: HLA-A, HLA-B, HLA-C, B2M, HLA-DPA, HLA-DQ, HLA-DRA, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, CIITA and combinations thereof, preferably selected from HLA-A, HLA-B, HLA-C, B2M, RFX5 , RFXAP, RFXANK, CIITA, and combinations thereof.
在一个实施方案中,所述表达本发明的包含LIR1抗体的嵌合受体的工程化免疫细胞进一步包括至少一种TCR/CD3基因的表达被抑制或沉默,所述TCR/CD3基因的实例包括例如TRAC、TRBC、CD3γ、CD3δ、CD3ε、CD3ζ。In one embodiment, the engineered immune cells expressing the chimeric receptor comprising the LIR1 antibody of the present invention further comprise that the expression of at least one TCR/CD3 gene is inhibited or silenced, examples of which include For example TRAC, TRBC, CD3γ, CD3δ, CD3ε, CD3ζ.
在一个优选的实施方案中,所述表达本发明的嵌合受体的工程化免疫细胞包括至少一种TCR/CD3基因和至少一种MHC相关基因的表达被抑制或沉默,其中所述至少一种TCR/CD3基因选自TRAC、TRBC、CD3γ、CD3δ、CD3ε、CD3ζ和它们的组合;所述至少一种MHC相关基因选自HLA-A、HLA-B、HLA-C、B2M、HLA-DPA、HLA-DQ、HLA-DRA、TAP1、TAP2、LMP2、LMP7、RFX5、RFXAP、RFXANK、CIITA和它们的组合,优选选自HLA-A、HLA-B、HLA-C、B2M、RFX5、RFXAP、RFXANK、CIITA和它们的组合。In a preferred embodiment, the engineered immune cells expressing the chimeric receptors of the present invention comprise suppressed or silenced expression of at least one TCR/CD3 gene and at least one MHC-related gene, wherein the at least one A kind of TCR/CD3 gene is selected from TRAC, TRBC, CD3γ, CD3δ, CD3ε, CD3ζ and their combination; Said at least one MHC-related gene is selected from HLA-A, HLA-B, HLA-C, B2M, HLA-DPA , HLA-DQ, HLA-DRA, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, CIITA and combinations thereof, preferably selected from HLA-A, HLA-B, HLA-C, B2M, RFX5, RFXAP, RFXANK, CIITA and their combination.
在一个优选的实施方案中,所述至少一种TCR/CD3基因选自TRAC、TRBC和它们的组合,所述至少一种MHC相关基因选自B2M、RFX5、RFXAP、RFXANK、CIITA和它们的组合。在一个实施方案中,所述工程化免疫细胞的TRAC或TRBC,和B2M的表达被抑制或沉默。在一个实施方案中,所述工程化免疫细胞的TRAC或TRBC,和CIITA的表达被抑制或沉默。在一个优选的实施方案中,所述工程化免疫细胞的TRAC或TRBC、B2M和CIITA的表达被抑制或沉默。在一个优选的实施方案中,所述工程化免疫细胞的TRAC或TRBC、B2M和RFX5的表达被抑制或沉默。In a preferred embodiment, the at least one TCR/CD3 gene is selected from the group consisting of TRAC, TRBC, and combinations thereof, and the at least one MHC-related gene is selected from the group consisting of B2M, RFX5, RFXAP, RFXANK, CIITA, and combinations thereof . In one embodiment, the expression of TRAC or TRBC, and B2M of the engineered immune cells is inhibited or silenced. In one embodiment, the expression of TRAC or TRBC, and CIITA of the engineered immune cells is inhibited or silenced. In a preferred embodiment, the expression of TRAC or TRBC, B2M and CIITA of the engineered immune cells is inhibited or silenced. In a preferred embodiment, the expression of TRAC or TRBC, B2M and RFX5 of the engineered immune cells is inhibited or silenced.
抑制基因表达或使基因沉默的方法是本领域技术人员熟知的,包括但不限于例如通过大范围核酸酶、锌指核酸酶、TALE核酸酶或CRISPR系统中的Cas酶介导DNA断裂、或通过反义寡核苷酸、RNAi、shRNA等技术使基因失活。Methods of inhibiting gene expression or silencing genes are well known to those of skill in the art and include, but are not limited to, DNA fragmentation mediated by, for example, meganucleases, zinc finger nucleases, TALE nucleases, or Cas enzymes in the CRISPR system, or by Antisense oligonucleotides, RNAi, shRNA and other technologies inactivate genes.
在一个实施方案中,本发明提供的工程化免疫细胞还表达靶向肿瘤抗原的嵌合抗原受体。In one embodiment, the engineered immune cells provided by the present invention further express chimeric antigen receptors targeting tumor antigens.
在一个实施方案中,所述嵌合抗原受体靶向选自以下的肿瘤抗原:TSHR、CD19、CD123、CD22、CD30、CD171、CS-1、CLL-1、CD33、EGFRvIII、GD2、GD3、BCMA、Tn Ag、PSMA、ROR1、FLT3、FAP、TAG72、CD38、CD44v6、CEA、EPCAM、B7H3、KIT、IL-13Ra2、间皮素、IL-l lRa、PSCA、PRSS21、VEGFR2、LewisY、CD24、PDGFR-β、SSEA-4、CD20、Folate受体α、ERBB2(Her2/neu)、 MUC1、EGFR、NCAM、Prostase、PAP、ELF2M、Ephrin B2、IGF-I受体、CAIX、LMP2、gplOO、bcr-abl、酪氨酸酶、EphA2、Fucosyl GMl、sLe、GM3、TGS5、HMWMAA、o-乙酰基-GD2、Folate受体β、TEM1/CD248、TEM7R、CLDN6、GPRC5D、CXORF61、CD97、CD 179a、ALK、多聚唾液酸、PLAC1、GloboH、NY-BR-1、UPK2、HAVCR1、ADRB3、PANX3、GPR20、LY6K、OR51E2、TARP、WT1、NY-ESO-1、LAGE-la、MAGE-A1、豆荚蛋白、HPV E6、E7、MAGE Al、ETV6-AML、精子蛋白17、XAGE1、Tie 2、MAD-CT-1、MAD-CT-2、Fos相关抗原1、p53、p53突变体、前列腺特异性蛋白、存活蛋白和端粒酶、PCTA-l/Galectin 8、MelanA/MARTl、Ras突变体、hTERT、肉瘤易位断点、ML-IAP、ERG(TMPRSS2ETS融合基因)、NA17、PAX3、雄激素受体、Cyclin Bl、MYCN、RhoC、TRP-2、CYP1B 1、BORIS、SART3、PAX5、OY-TES 1、LCK、AKAP-4、SSX2、RAGE-1、人端粒酶逆转录酶、RU1、RU2、肠道羧酸酯酶、mut hsp70-2、CD79a、CD79b、CD72、LAIR1、FCAR、LILRA2、CD300LF、CLEC12A、BST2、EMR2、LY75、GPC3、FCRL5、IGLL1、PD1、PDL1、PDL2、TGFβ、APRIL、Claudin18.2、NKG2D和它们的任意组合。优选地,所述靶标选自:CD19、CD20、CD22、BAFF-R、CD33、EGFRvIII、BCMA、GPRC5D、PSMA、ROR1、FAP、ERBB2(Her2/neu)、MUC1、EGFR、CAIX、WT1、NY-ESO-1、CD79a、CD79b、GPC3、Claudin18.2、NKG2D和它们的任意组合。根据待靶向的抗原,本发明的CAR可以被设计为包括对该抗原具有特异性的配体结合结构域。例如,如果CD19是待靶向的抗原,则CD19抗体可用作本发明的配体结合结构域。In one embodiment, the chimeric antigen receptor targets a tumor antigen selected from the group consisting of TSHR, CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, mesothelin, IL-11Ra, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-β, SSEA-4, CD20, Folate receptor α, ERBB2(Her2/neu), MUC1, EGFR, NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gplOO, bcr -abl, tyrosinase, EphA2, Fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, Folate receptor beta, TEM1/CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-la, MAGE-A1, Pod Protein, HPV E6, E7, MAGE Al, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-associated antigen 1, p53, p53 mutant, prostate specific protein , survivin and telomerase, PCTA-1/Galectin 8, MelanA/MART1, Ras mutant, hTERT, sarcoma translocation breakpoint, ML-IAP, ERG (TMPRSS2ETS fusion gene), NA17, PAX3, androgen receptor , Cyclin Bl, MYCN, RhoC, TRP-2, CYP1B 1, BORIS, SART3, PAX5, OY-TES 1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, Intestinal carboxylesterase, muhsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, PD1, PDL1, PDL2, TGFβ, APRIL, Claudin18.2, NK G2D and any combination of them. Preferably, the target is selected from: CD19, CD20, CD22, BAFF-R, CD33, EGFRvIII, BCMA, GPRC5D, PSMA, ROR1, FAP, ERBB2(Her2/neu), MUCl, EGFR, CAIX, WT1, NY- ESO-1, CD79a, CD79b, GPC3, Claudin18.2, NKG2D and any combination thereof. Depending on the antigen to be targeted, the CAR of the present invention can be designed to include a ligand binding domain specific for that antigen. For example, if CD19 is the antigen to be targeted, an antibody to CD19 can be used as the ligand binding domain of the invention.
如本文所用,术语“免疫细胞”是指免疫系统的具有一种或多种效应子功能(例如,细胞毒性细胞杀伤活性、分泌细胞因子、诱导ADCC和/或CDC)的任何细胞。例如,免疫细胞可以是T细胞、巨噬细胞、树突状细胞、单核细胞、NK细胞和/或NKT细胞。在一个实施方案中,免疫细胞衍生自干细胞,例如成体干细胞、胚胎干细 胞、脐带血干细胞、祖细胞、骨髓干细胞、诱导多能干细胞、全能干细胞或造血干细胞等。优选地,免疫细胞是T细胞。T细胞可以是任何T细胞,如体外培养的T细胞,例如原代T细胞,或者来自体外培养的T细胞系例如Jurkat、SupT1等的T细胞,或获得自受试者的T细胞。受试者的实例包括人、狗、猫、小鼠、大鼠及其转基因物种。T细胞可以从多种来源获得,包括外周血单核细胞、骨髓、淋巴结组织、脐血、胸腺组织、来自感染部位的组织、腹水、胸膜积液、脾组织及肿瘤。T细胞也可以被浓缩或纯化。T细胞可以处于任何发育阶段,包括但不限于,CD4+/CD8+T细胞、CD4+辅助T细胞(例如Th1和Th2细胞)、CD8+T细胞(例如,细胞毒性T细胞)、肿瘤浸润细胞、记忆T细胞、幼稚T细胞、γδ-T细胞、αβ-T细胞等。在一个优选的实施方案中,免疫细胞是人T细胞。可以使用本领域技术人员已知的多种技术,如Ficoll分离从受试者的血液获得T细胞。As used herein, the term "immune cell" refers to any cell of the immune system that has one or more effector functions (eg, cytotoxic cell killing activity, secretion of cytokines, induction of ADCC and/or CDC). For example, the immune cells can be T cells, macrophages, dendritic cells, monocytes, NK cells, and/or NKT cells. In one embodiment, the immune cells are derived from stem cells, such as adult stem cells, embryonic stem cells, umbilical cord blood stem cells, progenitor cells, bone marrow stem cells, induced pluripotent stem cells, totipotent stem cells, or hematopoietic stem cells, and the like. Preferably, the immune cells are T cells. The T cells can be any T cells, such as T cells cultured in vitro, eg, primary T cells, or T cells from T cell lines cultured in vitro, such as Jurkat, SupT1, etc., or T cells obtained from a subject. Examples of subjects include humans, dogs, cats, mice, rats, and transgenic species thereof. T cells can be obtained from a variety of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from sites of infection, ascites, pleural effusion, spleen tissue, and tumors. T cells can also be concentrated or purified. T cells can be at any stage of development, including, but not limited to, CD4+/CD8+ T cells, CD4+ helper T cells (eg, Th1 and Th2 cells), CD8+ T cells (eg, cytotoxic T cells), tumor-infiltrating cells, memory T cells, naive T cells, γδ-T cells, αβ-T cells, etc. In a preferred embodiment, the immune cells are human T cells. T cells can be obtained from the blood of a subject using a variety of techniques known to those of skill in the art, such as Ficoll separation.
采用本领域已知的常规方法(如通过转导、转染、转化等)可以将编码嵌合受体的核酸序列引入免疫细胞。“转染”是将核酸分子或多核苷酸(包括载体)引入靶细胞的过程。一个例子是RNA转染,即将RNA(比如体外转录的RNA,ivtRNA)引入宿主细胞的过程。该术语主要用于真核细胞中的非病毒方法。术语“转导”通常用于描述病毒介导的核酸分子或多核苷酸的转移。动物细胞的转染通常涉及在细胞膜中打开瞬时的孔或“洞”,以允许摄取材料。可以使用磷酸钙、通过电穿孔、通过细胞挤压或通过将阳离子脂质与材料混合以产生与细胞膜融合并将它们的运载物沉积入内部的脂质体,进行转染。用于转染真核宿主细胞的示例性技术包括脂质囊泡介导的摄取、热休克介导的摄取、磷酸钙介导的转染(磷酸钙/DNA共沉淀)、显微注射和电穿孔。术语“转化”用于描述核酸分子或多核苷酸(包括载体)向细菌中、也向非动物真核细胞(包括植物细胞)中的非病毒转移。因此,转化是细菌或非动物真核细胞的基因改变,其通过细胞膜从其周围直接摄取并随后并入外源遗传材料(核酸分子)而产生。 转化可以通过人工手段实现。为了发生转化,细胞或细菌必须处于感受态的状态。对于原核转化,技术可包括热休克介导的摄取、与完整细胞的细菌原生质体融合、显微注射和电穿孔。将核酸或载体引入免疫细胞后,本领域技术人员可以通过常规技术对所得免疫细胞进行扩增和活化。Nucleic acid sequences encoding chimeric receptors can be introduced into immune cells using conventional methods known in the art (eg, by transduction, transfection, transformation, etc.). "Transfection" is the process of introducing a nucleic acid molecule or polynucleotide, including a vector, into a target cell. An example is RNA transfection, the process of introducing RNA (eg, in vitro transcribed RNA, ivtRNA) into a host cell. The term is mainly used for non-viral methods in eukaryotic cells. The term "transduction" is generally used to describe virus-mediated transfer of nucleic acid molecules or polynucleotides. Transfection of animal cells typically involves opening transient pores or "holes" in the cell membrane to allow uptake of material. Transfection can be performed using calcium phosphate, by electroporation, by cell extrusion, or by mixing cationic lipids with materials to create liposomes that fuse with cell membranes and deposit their cargo inside. Exemplary techniques for transfecting eukaryotic host cells include lipid vesicle-mediated uptake, heat shock-mediated uptake, calcium phosphate-mediated transfection (calcium phosphate/DNA co-precipitation), microinjection, and electroporation. perforation. The term "transformation" is used to describe the non-viral transfer of nucleic acid molecules or polynucleotides (including vectors) into bacteria, but also into non-animal eukaryotic cells (including plant cells). Thus, transformation is the genetic alteration of a bacterial or non-animal eukaryotic cell, which is produced by the direct uptake of the cell membrane from its surroundings and subsequent incorporation of exogenous genetic material (nucleic acid molecules). Conversion can be achieved by manual means. For transformation to occur, the cells or bacteria must be in a competent state. For prokaryotic transformation, techniques can include heat shock-mediated uptake, fusion of bacterial protoplasts with intact cells, microinjection, and electroporation. After the nucleic acid or vector is introduced into immune cells, those skilled in the art can expand and activate the resulting immune cells by conventional techniques.
在一个实施方案中,本发明提供多种工程化免疫细胞,其中一种免疫细胞表达本发明所述的嵌合受体,另一种免疫细胞表达靶向其他NK抑制性受体的第二嵌合受体。在该实施方案中,所述第二嵌合受体包含第二NK抑制性配体、跨膜结构域和信号传导结构域,其中所述第二NK抑制性配体、跨膜结构域和信号传导结构域的定义如在“嵌合受体”一节中所述。还在另一个实施方案中,将一种免疫细胞改造为表达包含LIR1抗体的嵌合受体,并且将另一种免疫细胞改造为表达靶向肿瘤抗原的嵌合抗原受体。在此类实施方案中,所述多种工程化免疫细胞可以一起或单独施用。在一个实施方案中,所述多种免疫细胞可以在同一组合物中或在不同组合物中。细胞的示例性组合物包括本申请以下章节中所描述的组合物。In one embodiment, the present invention provides a plurality of engineered immune cells, wherein one immune cell expresses a chimeric receptor described herein and another immune cell expresses a second chimeric receptor targeting other NK inhibitory receptors combined receptors. In this embodiment, the second chimeric receptor comprises a second NK inhibitory ligand, a transmembrane domain, and a signaling domain, wherein the second NK inhibitory ligand, the transmembrane domain, and a signaling domain Conductive domains are defined as described in the "Chimeric Receptors" section. In yet another embodiment, one immune cell is engineered to express a chimeric receptor comprising a LIR1 antibody, and another immune cell is engineered to express a chimeric antigen receptor targeting a tumor antigen. In such embodiments, the plurality of engineered immune cells can be administered together or separately. In one embodiment, the plurality of immune cells may be in the same composition or in different compositions. Exemplary compositions of cells include those described in the following sections of this application.
抗体偶联物Antibody Conjugates
在一个方面,本发明提供一种抗体偶联物,其包含本发明所定义的LIR1抗体和第二功能性结构,其中所述第二功能性结构选自Fc、放射性同位素、延长半衰期的结构部分、可检测标记物和药物。In one aspect, the present invention provides an antibody conjugate comprising a LIR1 antibody as defined in the present invention and a second functional structure, wherein the second functional structure is selected from Fc, a radioisotope, a half-life extending moiety , detectable markers and drugs.
在一个实施方案中,本发明提供一种抗体偶联物,其包含本发明所定义的LIR1抗体和Fc。如本文所用,术语“Fc”用于定义免疫球蛋白重链的C末端区,其包括天然Fc和变体Fc。“天然Fc”是指包含通过消化完整抗体产生的、无论是单体形式或是多聚体形式的非抗原结合片段的分子或序列。产生天然Fc的免疫球蛋白源优选来源于人类。天然Fc片段由可以通过共价连接(例如二硫键)和非共价连接而连接为二聚体或多聚体形式的单体多肽构成。根据类别(例如IgG、IgA、IgE、IgD、IgM)或亚型(例如IgG1、IgG2、IgG3、IgA1、IgGA2)的不同,天然Fc分子单体亚基之间具有1-4 个分子间二硫键。天然Fc的一个实例是通过用木瓜蛋白酶消化IgG产生的二硫键连接的二聚体(参见Ellison等(1982),Nucleic Acids Res.10:4071-9)。本文所用的术语“天然Fc”一般是指单体、二聚体和多聚体形式。“变体Fc”是指由于至少一个本文定义的“氨基酸修饰”而与“天然”或“野生型”Fc的氨基酸序列不同的氨基酸序列,也称为“Fc变体”。因此,“Fc”也包括单链Fc(scFc),即,由多肽接头连接的两个Fc单体组成的单链Fc,其能够自然折叠成功能性二聚体Fc区域。在一个实施方案中,所述Fc优选是人免疫球蛋白的Fc,更优选是人IgG1的Fc。In one embodiment, the present invention provides an antibody conjugate comprising a LIR1 antibody as defined in the present invention and an Fc. As used herein, the term "Fc" is used to define the C-terminal region of an immunoglobulin heavy chain, which includes native Fc and variant Fc. "Native Fc" refers to a molecule or sequence comprising a non-antigen-binding fragment, whether in monomeric or multimeric form, produced by digestion of an intact antibody. The source of immunoglobulins for the production of native Fc is preferably derived from humans. Native Fc fragments are composed of monomeric polypeptides that can be linked in dimeric or multimeric form by covalent linkages (eg, disulfide bonds) and non-covalent linkages. Depending on the class (eg IgG, IgA, IgE, IgD, IgM) or subtype (eg IgG1, IgG2, IgG3, IgA1, IgGA2), there are 1-4 intermolecular disulfides between the monomeric subunits of native Fc molecules key. An example of a native Fc is the disulfide-linked dimer produced by papain digestion of IgG (see Ellison et al. (1982) Nucleic Acids Res. 10:4071-9). The term "native Fc" as used herein generally refers to monomeric, dimeric and multimeric forms. "Variant Fc" refers to an amino acid sequence that differs from that of a "native" or "wild-type" Fc due to at least one "amino acid modification" as defined herein, also referred to as an "Fc variant". Thus, "Fc" also includes single-chain Fc (scFc), ie, a single-chain Fc consisting of two Fc monomers linked by a polypeptide linker, which is capable of naturally folding into a functional dimeric Fc region. In one embodiment, the Fc is preferably a human immunoglobulin Fc, more preferably a human IgGl Fc.
在一个实施方案中,本发明提供一种抗体偶联物,其包含本发明所定义的LIR1抗体和放射性同位素。可用于本发明的放射性同位素的实例包括但不限于At
211、I
131、I
125、Y
90、Re
186、Re
188、Sm
153、Bi
212、P
32、Pb
212、
99mTc、
123I、
18F和
68Ga。
In one embodiment, the present invention provides an antibody conjugate comprising a LIR1 antibody as defined in the present invention and a radioisotope. Examples of radioisotopes useful in the present invention include, but are not limited to, At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 , 99m Tc, 123 I, 18 F and 68 Ga.
在一个实施方案中,本发明提供一种抗体偶联物,其包含本发明所定义的LIR1抗体和延长半衰期的结构部分,所述延长半衰期的结构部分选自白蛋白的结合结构、转铁蛋白的结合结构、聚乙二醇分子、重组聚乙二醇分子、人血清白蛋白、人血清白蛋白的片段和结合人血清白蛋白的白多肽(包括抗体)。In one embodiment, the present invention provides an antibody conjugate comprising the LIR1 antibody as defined in the present invention and a half-life extending moiety selected from the group consisting of the binding structure of albumin, the Binding structures, polyethylene glycol molecules, recombinant polyethylene glycol molecules, human serum albumin, fragments of human serum albumin, and white polypeptides (including antibodies) that bind human serum albumin.
在一个实施方案中,本发明提供一种抗体偶联物,其包含本发明所定义的LIR1抗体和可检测标记物。术语“可检测标记物”在本文中意指产生可检测信号的化合物。例如,可检测标记物可以是MRI造影剂、闪烁扫描造影剂、X射线成像造影剂、超声造影剂、光学成像造影剂。可检测标记物的实施例包括荧光团(如荧光素、Alexa或花青)、化学发光化合物(如鲁米诺)、生物发光化合物(如荧光素酶或碱性磷酸酶)、酶(如辣根过氧化物酶、葡萄糖-6-磷酸酶、β-半乳糖苷酶)、抗生素(例如卡那霉素、氨苄霉素、氯霉素、四环素等)抗性基因和造影剂(如纳米颗粒或钆)。本领域技术人员可以根据所用的检测系统选择合适的可检测标记物。In one embodiment, the present invention provides an antibody conjugate comprising a LIR1 antibody as defined in the present invention and a detectable label. The term "detectable label" herein means a compound that produces a detectable signal. For example, the detectable label can be an MRI contrast agent, a scintigraphic contrast agent, an X-ray imaging contrast agent, an ultrasound contrast agent, an optical imaging contrast agent. Examples of detectable labels include fluorophores (such as fluorescein, Alexa, or cyanine), chemiluminescent compounds (such as luminol), bioluminescent compounds (such as luciferase or alkaline phosphatase), enzymes (such as Root peroxidase, glucose-6-phosphatase, β-galactosidase), antibiotics (such as kanamycin, ampicillin, chloramphenicol, tetracycline, etc.) resistance genes and contrast agents (such as nanoparticles or gadolinium). Those skilled in the art can select appropriate detectable labels depending on the detection system used.
在一个实施方案中,本发明提供一种抗体偶联物,其包含本发 明所定义的LIR1抗体和与所述LIR1抗体偶联的药物,例如细胞毒素或免疫调节剂(即,抗体药物偶联物)。通常药物通过共价与抗体连接,并且通常依赖于接头。在一个实施方案中,所述药物是细胞毒素。在另一个实施方案中,所述药物是免疫调节剂。细胞毒素的实例包括但不限于甲氨蝶呤、氨基蝶呤、6-巯基嘌呤、6-硫鸟嘌呤、阿糖胞苷、5-氟尿嘧啶、达卡巴嗪、氮芥、噻替派、苯丁酸氮芥、美法仑、卡莫司汀(BSNU)、洛莫司汀(CCNU)、1-甲基亚硝基脲、环磷酰胺、氮芥、白消安、二溴甘露醇、链佐星、丝裂霉素、顺-二氯二胺铂(II)(DDP)、顺铂、卡铂、佐柔比星、多柔比星、地托比星、卡米诺霉素、伊达比星、表柔比星、米托蒽醌、放线菌素D、博来霉素、刺孢霉素、光辉霉素、安曲霉素(AMC)、长春新碱、长春花碱、紫杉醇、蓖麻毒素、假单胞菌外毒素、吉西他滨、细胞松弛素B、短杆菌肽D、溴乙锭、依米丁、依托泊苷、替尼泊苷、秋水仙素、二羟基蒽二酮、1-脱氢睾酮、糖皮质激素、普鲁卡因、丁卡因、利多卡因、普萘洛尔、嘌呤霉素、丙卡巴肼、羟基脲、天冬酰胺酶、皮质类固醇、米托坦(O,P'-(DDD))、干扰素,以及它们的组合。免疫调节剂的实例包括但不限于更昔洛韦、依那西普、他克莫司、西罗莫司、伏环孢素、环孢灵、雷帕霉素、环磷酰胺、硫唑嘌呤、霉酚酸酯、甲氨蝶呤、糖皮质素及其类似物、细胞因子、干细胞生长因子、淋巴毒素、肿瘤坏死因子(TNF)、造血因子、白介素(例如IL-1、IL-2、IL-3、IL-6、IL-10、IL-12、IL-18及IL-21)、集落刺激因子(例如G-CSF及(GM-CSF)、干扰素(例如干扰素-α、干扰素-β及干扰素-γ)、命名为“S1因子”的干细胞生长因子、红细胞生成素和血小板生成素,或其组合。In one embodiment, the present invention provides an antibody conjugate comprising a LIR1 antibody as defined in the present invention and a drug, such as a cytotoxin or an immunomodulatory agent (ie, an antibody drug conjugate), conjugated to the LIR1 antibody thing). Usually the drug is covalently attached to the antibody and usually relies on a linker. In one embodiment, the drug is a cytotoxin. In another embodiment, the drug is an immunomodulatory agent. Examples of cytotoxins include, but are not limited to, methotrexate, aminopterin, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil, dacarbazine, nitrogen mustard, thiotepa, benzidine Nitrogen mustard, melphalan, carmustine (BSNU), lomustine (CCNU), 1-methylnitrosourea, cyclophosphamide, nitrogen mustard, busulfan, dibromomannitol, chain Zocin, mitomycin, cis-dichlorodiamineplatinum (II) (DDP), cisplatin, carboplatin, zorubicin, doxorubicin, detorubicin, caminomycin, Darubicin, epirubicin, mitoxantrone, actinomycin D, bleomycin, calicheamicin, glaremycin, atramycin (AMC), vincristine, vinblastine, Paclitaxel, Ricin, Pseudomonas Exotoxin, Gemcitabine, Cytochalasin B, Gramicidin D, Ethidium Bromide, Emetine, Etoposide, Teniposide, Colchicine, Dihydroxyanthracene Ketones, 1-Dehydrotestosterone, Glucocorticoids, Procaine, Tetracaine, Lidocaine, Propranolol, Puromycin, Procarbazine, Hydroxyurea, Asparaginase, Corticosteroids, Rice Totane (O,P'-(DDD)), interferon, and combinations thereof. Examples of immunomodulators include, but are not limited to, ganciclovir, etanercept, tacrolimus, sirolimus, vortexporine, cyclosporine, rapamycin, cyclophosphamide, azathioprine , mycophenolate mofetil, methotrexate, glucocorticoids and their analogs, cytokines, stem cell growth factors, lymphotoxins, tumor necrosis factor (TNF), hematopoietic factors, interleukins (such as IL-1, IL-2, IL-3, IL-6, IL-10, IL-12, IL-18 and IL-21), colony stimulating factors such as G-CSF and (GM-CSF), interferons such as interferon-alpha, interferon interferon-beta and interferon-gamma), stem cell growth factors designated "S1 factor", erythropoietin and thrombopoietin, or a combination thereof.
试剂盒和药物组合物Kits and Pharmaceutical Compositions
在另一个方面,本发明还提供一种检测试剂盒,其包含本发明所述的抗体、多特异性抗体、嵌合受体或抗体偶联物。In another aspect, the present invention also provides a detection kit comprising the antibody, multispecific antibody, chimeric receptor or antibody conjugate of the present invention.
在另一个方面,本发明还提供一种药物组合物,其包含本发明所述的抗体、多特异性抗体、嵌合受体、工程化免疫细胞或抗体偶 联物,和一种或多种药学上可接受的赋形剂。In another aspect, the present invention also provides a pharmaceutical composition comprising the antibody, multispecific antibody, chimeric receptor, engineered immune cell or antibody conjugate of the present invention, and one or more Pharmaceutically acceptable excipients.
如本文所用,术语“药学上可接受的赋型剂”是指在药理学和/或生理学上与受试者和活性成分相容(即,能够引发所需的治疗效果而不会引起任何不希望的局部或全身作用)的载体和/或赋形剂,其是本领域公知的(参见例如Remington's Pharmaceutical Sciences.Edited by Gennaro AR,19th ed.Pennsylvania:Mack Publishing Company,1995)。药学上可接受的赋型剂的实例包括但不限于填充剂、粘合剂、崩解剂、包衣剂、吸附剂、抗粘附剂、助流剂、抗氧化剂、调味剂、着色剂、甜味剂、溶剂、共溶剂、缓冲剂、螯合剂、表面活性剂、稀释剂、润湿剂、防腐剂、乳化剂、包覆剂、等渗剂、吸收延迟剂、稳定剂和张力调节剂。本领域技术人员已知选择合适的赋型剂以制备本发明期望的药物组合物。用于本发明的药物组合物中的示例性赋型剂包括盐水、缓冲盐水、葡萄糖和水。通常,合适的赋形剂的选择尤其取决于所使用的活性剂、待治疗的疾病和药物组合物的期望剂型。As used herein, the term "pharmaceutically acceptable excipient" means pharmacologically and/or physiologically compatible with the subject and the active ingredient (ie, capable of eliciting the desired therapeutic effect without causing any inconvenience desired local or systemic effect) carriers and/or excipients, which are well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995). Examples of pharmaceutically acceptable excipients include, but are not limited to, fillers, binders, disintegrants, coatings, adsorbents, antiadherents, glidants, antioxidants, flavoring agents, colorants, Sweeteners, solvents, co-solvents, buffers, chelating agents, surfactants, diluents, wetting agents, preservatives, emulsifiers, coating agents, isotonic agents, absorption delaying agents, stabilizers and tonicity modifiers . It is known to those skilled in the art to select suitable excipients to prepare the desired pharmaceutical compositions of the present invention. Exemplary excipients for use in the pharmaceutical compositions of the present invention include saline, buffered saline, dextrose and water. In general, the selection of suitable excipients depends, among other things, on the active agent used, the disease to be treated and the desired dosage form of the pharmaceutical composition.
根据本发明的药物组合物可适用于多种途径施用。通常,通过胃肠外完成施用。胃肠外递送方法包括局部、动脉内、肌内、皮下、髓内、鞘内、心室内、静脉内、腹膜内、子宫内、阴道内、舌下或鼻内施用。The pharmaceutical compositions according to the present invention may be suitable for administration by various routes. Typically, administration is accomplished parenterally. Parenteral delivery methods include topical, intraarterial, intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, intrauterine, intravaginal, sublingual or intranasal administration.
根据本发明的药物组合物也可以制备成各种形式,如固态、液态、气态或冻干形式,特别可以是软膏、乳膏、透皮贴剂、凝胶、粉末、片剂、溶液、气雾剂、颗粒、丸剂、混悬剂、乳剂、胶囊、糖浆、酏剂、浸膏剂、酊剂或流浸膏提取物的形式,或者是特别适用于所需施用方法的形式。本发明已知的用于生产药物的过程可包括例如常规混合、溶解、制粒、制糖衣、研磨、乳化、包封、包埋或冻干过程。包含例如本文所述的免疫细胞的药物组合物通常以溶液形式提供,并且优选包含药学上可接受的缓冲剂。The pharmaceutical compositions according to the invention can also be prepared in various forms, such as solid, liquid, gaseous or lyophilized forms, in particular ointments, creams, transdermal patches, gels, powders, tablets, solutions, gaseous In the form of aerosols, granules, pills, suspensions, emulsions, capsules, syrups, elixirs, extracts, tinctures or liquid extracts, or in a form particularly suitable for the desired method of administration. Processes known in the present invention for the manufacture of pharmaceuticals may include, for example, conventional mixing, dissolving, granulating, dragee-making, milling, emulsifying, encapsulating, entrapping, or lyophilizing processes. Pharmaceutical compositions comprising immune cells such as those described herein are typically provided in solution and preferably comprise a pharmaceutically acceptable buffer.
根据本发明的药物组合物还可以与一种或多种适用于治疗和/或预防待治疗疾病的其它药剂组合施用。适用于组合的药剂的优选实 例包括已知的抗癌药物,比如顺铂、美登素衍生物、雷查霉素(rachelmycin)、卡里奇霉素(calicheamicin)、多西紫杉醇、依托泊苷、吉西他滨、异环磷酰胺、伊立替康、美法仑、米托蒽醌、sorfimer卟啉钠II(sorfimer sodiumphotofrin II)、替莫唑胺、拓扑替康、葡萄糖醛酸曲美沙特(trimetreate glucuronate)、奥利斯他汀E(auristatin E)、长春新碱和阿霉素;肽细胞毒素,比如蓖麻毒素、白喉毒素、假单胞菌细菌外毒素A、DNA酶和RNA酶;放射性核素,比如碘131、铼186、铟111、铱90、铋210和213、锕225和砹213;前药,比如抗体定向的酶前药;免疫刺激剂,比如血小板因子4、黑色素瘤生长刺激蛋白等;抗体或其片段,比如抗CD3抗体或其片段,补体活化剂,异种蛋白结构域,同种蛋白结构域,病毒/细菌蛋白结构域和病毒/细菌肽。此外,本发明的药物组合物也可以与其他一种或多种治疗方法,例如化疗、放疗组合使用。The pharmaceutical compositions according to the present invention may also be administered in combination with one or more other agents suitable for the treatment and/or prevention of the disease to be treated. Preferred examples of agents suitable for combination include known anticancer drugs such as cisplatin, maytansine derivatives, rachelmycin, calicheamicin, docetaxel, etoposide , gemcitabine, ifosfamide, irinotecan, melphalan, mitoxantrone, sorfimer sodium photofrin II, temozolomide, topotecan, trimetate glucuronate, auristatin E, vincristine and doxorubicin; peptide cytotoxins such as ricin, diphtheria toxin, Pseudomonas bacterial exotoxin A, DNase and RNase; radionuclides such as iodine 131, rhenium 186, indium 111, iridium 90, bismuth 210 and 213, actinium 225 and astatine 213; prodrugs, such as antibody-directed enzyme prodrugs; immunostimulants, such as platelet factor 4, melanoma growth-stimulating protein, etc.; antibodies or fragments thereof, such as anti-CD3 antibodies or fragments thereof, complement activators, heterologous protein domains, homologous protein domains, viral/bacterial protein domains and viral/bacterial peptides. In addition, the pharmaceutical composition of the present invention can also be used in combination with one or more other treatment methods, such as chemotherapy and radiotherapy.
治疗/预防/诊断用途Therapeutic/Prophylactic/Diagnostic Use
在另一个方面,本发明还提供一种治疗和/或预防和/或诊断与LIR1表达相关的疾病的方法,包括向受试者施用如上所述的抗体、嵌合受体、多特异性抗体、抗体偶联物、工程化免疫细胞或药物组合物。In another aspect, the present invention also provides a method of treating and/or preventing and/or diagnosing a disease associated with LIR1 expression, comprising administering to a subject an antibody, chimeric receptor, multispecific antibody as described above , antibody conjugates, engineered immune cells or pharmaceutical compositions.
在一个实施方案中,与LIR1表达相关的疾病包括但不限于:急性早幼粒细胞白血病、急性粒-单核细胞白血病、急性单核细胞白血病、红白血病、急性巨核细胞白血病;慢性白血病,例如慢性髓细胞白血病、慢性淋巴细胞白血病、慢性单核细胞白血病;和其他特殊类型的白血病例如毛细胞白血病、幼淋巴细胞白血病、浆细胞白血病、成人T细胞白血病、嗜酸性粒细胞白血病、嗜碱性粒细胞白血病等)、母细胞性浆细胞样树突状细胞瘤、恶性淋巴组织增生疾病、Waldenstrom巨球蛋白血症、淋巴瘤(包括霍奇金淋巴瘤和非霍奇金淋巴瘤,例如B细胞淋巴瘤(包括低级/滤泡性非霍奇金淋巴瘤(NHL)、小淋巴细胞性(SL)NHL、中间级/滤泡性NHL、中间级扩散性NHL、高级成免疫细胞性NHL、高级成淋巴细胞性NHL、高级小 型非裂化细胞性NHL、大肿块病NHL)、套细胞淋巴瘤、AIDS相关淋巴瘤、伯基特氏淋巴瘤、弥散性大B细胞淋巴瘤、滤泡性淋巴瘤、MALT淋巴瘤、边缘区淋巴瘤、浆母细胞性淋巴瘤、浆细胞样树突状细胞瘤等)、NK细胞淋巴瘤、大颗粒淋巴细胞增殖性疾病、NK细胞白血病、白血病(包括急性白血病,例如急性淋巴细胞白血病、急性髓细胞白血病、急性非淋巴细胞白血病诸如急性粒细胞白血病(包括未分化型和部分分化型)、骨髓发育不良、多发性骨髓瘤、骨髓增生异常、移植后淋巴细胞增生性紊乱(PTLD)、组织细胞坏死性淋巴结炎、假性淋巴瘤、伴有毛细胞的脾淋巴瘤、脑神经胶质瘤、胚细胞瘤、肉瘤、基底细胞癌、胆道癌、膀胱癌、骨癌、脑和CNS癌症、乳腺癌、腹膜癌、宫颈癌、绒毛膜癌、结肠和直肠癌、结缔组织癌症、消化系统的癌症、子宫内膜癌、食管癌、眼癌、头颈癌、胃癌(包括胃肠癌)、胶质母细胞瘤(GBM)、肝癌、肝细胞瘤、上皮内肿瘤、肾癌、喉癌、肝肿瘤、肺癌(例如小细胞肺癌、非小细胞肺癌、腺状肺癌和鳞状肺癌)、黑色素瘤、骨髓瘤、神经母细胞瘤、口腔癌(例如唇、舌、口和咽)、卵巢癌、胰腺癌、前列腺癌、间皮瘤、视网膜母细胞瘤、横纹肌肉瘤、直肠癌、呼吸系统的癌症、唾液腺癌、皮肤癌、鳞状细胞癌、胃癌、睾丸癌、甲状腺癌、子宫或子宫内膜癌、泌尿系统的恶性肿瘤、外阴癌。优选地,可以用本发明的工程化免疫细胞或药物组合物治疗的疾病选自:单核/巨噬细胞功能异常疾病、白血病、淋巴瘤、多发性骨髓瘤、脑神经胶质瘤、胰腺癌、胃癌等。In one embodiment, diseases associated with LIR1 expression include, but are not limited to: acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, erythroleukemia, acute megakaryocytic leukemia; chronic leukemia, such as Chronic myeloid leukemia, chronic lymphocytic leukemia, chronic monocytic leukemia; and other special types of leukemia such as hairy cell leukemia, prolymphocytic leukemia, plasma cell leukemia, adult T-cell leukemia, eosinophilic leukemia, basophilic leukemia myeloid leukemia, etc.), blastic plasmacytoid dendritic cell tumor, malignant lymphoproliferative disorders, Waldenstrom macroglobulinemia, lymphomas (including Hodgkin lymphoma and non-Hodgkin lymphoma such as B Cell lymphomas (including low-grade/follicular non-Hodgkin lymphoma (NHL), small lymphocytic (SL) NHL, intermediate-grade/follicular NHL, intermediate-grade diffuse NHL, high-grade immunoblastoid NHL, high-grade lymphoblastic NHL, high-grade small non-cleaving cell NHL, bulky NHL), mantle cell lymphoma, AIDS-related lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma tumor, MALT lymphoma, marginal zone lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell tumor, etc.), NK cell lymphoma, large granular lymphoproliferative disease, NK cell leukemia, leukemia (including acute Leukemias such as acute lymphoblastic leukemia, acute myeloid leukemia, acute non-lymphocytic leukemia such as acute myeloid leukemia (including undifferentiated and partially differentiated forms), myelodysplasia, multiple myeloma, myelodysplasia, post-transplant lymphoid Cell proliferative disorder (PTLD), histiocytic necrotizing lymphadenitis, pseudolymphoma, splenic lymphoma with hair cells, brain glioma, blastoma, sarcoma, basal cell carcinoma, biliary tract cancer, bladder cancer , bone cancer, brain and CNS cancer, breast cancer, peritoneal cancer, cervical cancer, choriocarcinoma, colon and rectal cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, Gastric cancer (including gastrointestinal cancer), glioblastoma (GBM), liver cancer, hepatocellular tumor, intraepithelial tumor, kidney cancer, laryngeal cancer, liver tumor, lung cancer (e.g. small cell lung cancer, non-small cell lung cancer, glandular lung and squamous lung cancer), melanoma, myeloma, neuroblastoma, oral cancer (e.g., lips, tongue, mouth, and pharynx), ovarian cancer, pancreatic cancer, prostate cancer, mesothelioma, retinoblastoma, rhabdoid Sarcoma, rectal cancer, cancer of the respiratory system, salivary gland cancer, skin cancer, squamous cell cancer, gastric cancer, testicular cancer, thyroid cancer, uterine or endometrial cancer, malignant tumor of the urinary system, vulvar cancer. The diseases treated by the engineered immune cells or the pharmaceutical composition of the present invention are selected from: monocyte/macrophage dysfunction diseases, leukemia, lymphoma, multiple myeloma, brain glioma, pancreatic cancer, gastric cancer and the like.
在另一个实施方案中,当本发明的包含抗LIR1抗体的嵌合受体与靶向肿瘤抗原的嵌合抗原受体在免疫细胞中共同表达或将分别表达两者的免疫细胞组合施用时,可以治疗的疾病取决于嵌合抗原受体靶向的肿瘤抗原。例如,当本发明的包含抗LIR1抗体的嵌合受体与靶向CD19的嵌合抗原受体共同表达或施用时,可以治疗的疾病是与CD19表达相关的疾病,例如B细胞恶性肿瘤,包括急性淋巴细胞白血病(B-ALL)、慢性B-淋巴细胞白血病(B-CLL),B细胞霍奇 金氏淋巴瘤(B-HL)和非霍奇金氏淋巴瘤(B-NHL)等。在该实施方案中,包含抗LIR1抗体的嵌合受体用于抑制NK细胞对回输的工程化免疫细胞的杀伤,而嵌合抗原受体用于通过与肿瘤抗原的结合来定向杀伤靶细胞。In another embodiment, when the anti-LIR1 antibody-containing chimeric receptor of the invention and the tumor antigen-targeting chimeric antigen receptor are co-expressed in immune cells or are administered in combination with immune cells expressing both, respectively, The diseases that can be treated depend on the tumor antigen targeted by the chimeric antigen receptor. For example, when a chimeric receptor of the invention comprising an anti-LIR1 antibody is co-expressed or administered with a chimeric antigen receptor targeting CD19, the diseases that can be treated are diseases associated with CD19 expression, such as B-cell malignancies, including Acute lymphocytic leukemia (B-ALL), chronic B-lymphocytic leukemia (B-CLL), B-cell Hodgkin's lymphoma (B-HL) and non-Hodgkin's lymphoma (B-NHL), etc. In this embodiment, a chimeric receptor comprising an anti-LIR1 antibody is used to inhibit killing of reinfused engineered immune cells by NK cells, while a chimeric antigen receptor is used to target cell killing through binding to tumor antigens .
下面将参考附图并结合实例来详细说明本发明。需要说明的是,本领域的技术人员应该理解本发明的附图及其实施例仅仅是为了例举的目的,并不能对本发明构成任何限制。在不矛盾的情况下,本申请中的实施例及实施例中的特征可以相互组合。The present invention will be described in detail below with reference to the accompanying drawings and in conjunction with examples. It should be noted that those skilled in the art should understand that the accompanying drawings and the embodiments of the present invention are only for the purpose of illustration and do not constitute any limitation to the present invention. The embodiments in the present application and the features in the embodiments may be combined with each other where there is no contradiction.
图1:示出了包含LIR1抗体的UNKi-T细胞的scFv表达水平。Figure 1: shows the level of scFv expression of UNKi-T cells containing LIR1 antibody.
图2:示出了包含LIR1抗体的UNKi-T细胞对NK细胞杀伤作用的抑制效果。用Two-way ANOVA分析,并用T test进行统计学分析。**表示P值小于0.01,达到显著水平。Figure 2: Shows the inhibitory effect of LIR1 antibody-containing UNKi-T cells on NK cell killing. Two-way ANOVA was used for analysis and statistical analysis was performed with T test. ** Indicates that the P value is less than 0.01, reaching a significant level.
实施例1.制备LIR1抗体Example 1. Preparation of LIR1 antibody
将含有LIR1蛋白胞外区序列克隆到带有His标签的pCP载体上,将测序正确的质粒瞬时感染CHO细胞,培养8-10天后收获细胞培养液,采用亲和层析方式进行蛋白纯化,获得人源LIR1蛋白胞外区,作为免疫原。The sequence containing the extracellular region of the LIR1 protein was cloned into a pCP vector with a His tag, and the correctly sequenced plasmid was transiently infected with CHO cells. After culturing for 8-10 days, the cell culture medium was harvested, and the protein was purified by affinity chromatography to obtain The extracellular domain of human LIR1 protein as an immunogen.
采用6-8周雌性Balb/c小鼠进行初次和加强免疫,采用ELISA和FACS检测血清中蛋白免疫原的抗体效价和特异性,综合评定后对小鼠进行最后一次强化免疫。3-4天后处死小鼠,收集脾细胞,将其按照一定比例与小鼠骨髓瘤细胞(SP2/0)混合,并将增殖后的杂交瘤细胞经由FACS和ELISA方法鉴定后筛选到阳性细胞株。经过多轮亚克隆鉴定,最终获得可稳定分泌LIR1抗体的两株杂交瘤细胞,将两株细胞上清中的抗体进行纯化后,获得LIR1-1和KIR1-2抗体。6-8 week old female Balb/c mice were used for primary and booster immunization, and ELISA and FACS were used to detect the antibody titer and specificity of protein immunogen in serum. After comprehensive evaluation, mice were given the last booster immunization. Mice were sacrificed after 3-4 days, spleen cells were collected, mixed with mouse myeloma cells (SP2/0) in a certain proportion, and the proliferated hybridoma cells were identified by FACS and ELISA, and positive cell lines were screened. . After several rounds of subcloning identification, two hybridoma cells that can stably secrete LIR1 antibody were finally obtained, and the LIR1-1 and KIR1-2 antibodies were obtained after the antibodies in the supernatants of the two cell lines were purified.
采用胰蛋白酶进行酶解抗体,通过DNA数据采集获得高质量的 一级和二级谱图,将谱图用peaks软件进行de novo解析后获得初步的氨基酸序列结果;采用多种蛋白酶对抗体进行酶解,MSE采集数据后可获得所有肽段峰以及每个肽段各个价态完整和碎裂的信息;将获得的更加全面的质谱数据与初步的氨基酸序列进行匹配,最终获得的两个LIR1单链抗体的氨基酸序列如下表1所示。Antibodies were digested with trypsin, high-quality primary and secondary spectra were obtained through DNA data acquisition, and the spectra were de novo analyzed with peaks software to obtain preliminary amino acid sequence results; a variety of proteases were used to digest antibodies Solution, after MSE collects data, all peptide peaks and the completeness and fragmentation information of each valence state of each peptide can be obtained; the obtained more comprehensive mass spectrometry data is matched with the preliminary amino acid sequence, and finally two LIR1 singles are obtained. The amino acid sequences of chain antibodies are shown in Table 1 below.
表1.LIR1 scFv的序列Table 1. Sequences of LIR1 scFvs
LIR1 scFv-1LIR1 scFv-1 | LIR1 scFv-2LIR1 scFv-2 | |
CDR-L1CDR-L1 | SEQ ID NO:1SEQ ID NO: 1 | SEQ ID NO:10SEQ ID NO: 10 |
CDR-L2CDR-L2 | SEQ ID NO:2SEQ ID NO: 2 | SEQ ID NO:11SEQ ID NO: 11 |
CDR-L3CDR-L3 | SEQ ID NO:3SEQ ID NO: 3 | SEQ ID NO:12SEQ ID NO: 12 |
CDR-H1CDR-H1 | SEQ ID NO:4SEQ ID NO: 4 | SEQ ID NO:13SEQ ID NO: 13 |
CDR-H2CDR-H2 | SEQ ID NO:5SEQ ID NO: 5 | SEQ ID NO:14SEQ ID NO: 14 |
CDR-H3CDR-H3 | SEQ ID NO:6SEQ ID NO: 6 | SEQ ID NO:15SEQ ID NO: 15 |
VLVL | SEQ ID NO:7SEQ ID NO: 7 | SEQ ID NO:16SEQ ID NO: 16 |
VHVH | SEQ ID NO:8SEQ ID NO: 8 | SEQ ID NO:17SEQ ID NO: 17 |
scFvscFv | SEQ ID NO:9SEQ ID NO: 9 | SEQ ID NO:18SEQ ID NO: 18 |
实施例2.制备表达包含LIR1抗体的嵌合受体的UNKi-T细胞Example 2. Preparation of UNKi-T cells expressing chimeric receptors comprising LIR1 antibodies
合成编码以下蛋白的序列,并将其克隆至pLVX载体(Public Protein/Plasmid Library(PPL),货号:PPL00157-4a):B2m信号肽(SEQ ID NO:33)、抗LIR1 scFv-1(SEQ ID NO:9)、IgG4铰链区(SEQ ID NO:41)、CD8α跨膜区(SEQ ID NO:21)、CD28共刺激结构域(SEQ ID NO:25),获得LIR1-1质粒,并通过测序确认目标序列在质粒中的正确插入。Sequences encoding the following proteins were synthesized and cloned into the pLVX vector (Public Protein/Plasmid Library (PPL), Cat. No.: PPL00157-4a): B2m signal peptide (SEQ ID NO: 33), anti-LIR1 scFv-1 (SEQ ID NO: 9), IgG4 hinge region (SEQ ID NO: 41), CD8α transmembrane region (SEQ ID NO: 21), CD28 costimulatory domain (SEQ ID NO: 25), LIR1-1 plasmid was obtained and sequenced Confirm the correct insertion of the target sequence into the plasmid.
合成编码以下蛋白的序列,并将其克隆至pLVX载体(Public Protein/Plasmid Library(PPL),货号:PPL00157-4a):CD8α信号肽(SEQ ID NO:35)、抗LIR1 scFv-2(SEQ ID NO:18)、CD28铰链区(SEQ ID NO:39)、CD28跨膜区(SEQ ID NO:23)、4-1BB共刺激结构域(SEQ ID NO:27),获得LIR1-2质粒,并通过测序 确认目标序列在质粒中的正确插入。Sequences encoding the following proteins were synthesized and cloned into the pLVX vector (Public Protein/Plasmid Library (PPL), Cat. No.: PPL00157-4a): CD8α signal peptide (SEQ ID NO: 35), anti-LIR1 scFv-2 (SEQ ID NO: 18), CD28 hinge region (SEQ ID NO: 39), CD28 transmembrane region (SEQ ID NO: 23), 4-1BB costimulatory domain (SEQ ID NO: 27) to obtain LIR1-2 plasmid, and Confirm the correct insertion of the target sequence in the plasmid by sequencing.
在无菌管中加入3ml Opti-MEM(Gibco,货号31985-070)稀释上述质粒后,再根据质粒:病毒包装载体:病毒包膜载体=4:2:1的比例加入包装载体psPAX2(Addgene,货号12260)和包膜载体pMD2.G(Addgene,货号12259)。然后,加入120ul X-treme GENE HP DNA转染试剂(Roche,货号06366236001),立即混匀,于室温下孵育15min,然后将质粒/载体/转染试剂混合物逐滴加入到293T细胞的培养瓶中。在24小时和48小时收集病毒,将其合并后,超速离心(25000g,4℃,2.5小时)获得浓缩的慢病毒。Add 3ml Opti-MEM (Gibco, Item No. 31985-070) to a sterile tube to dilute the above plasmid, and then add the packaging vector psPAX2 (Addgene, Cat. No. 12260) and the envelope vector pMD2.G (Addgene, Cat. No. 12259). Then, add 120ul of X-treme GENE HP DNA transfection reagent (Roche, Cat. No. 06366236001), mix immediately, incubate at room temperature for 15 min, and then add the plasmid/vector/transfection reagent mixture dropwise to the culture flask of 293T cells . Viruses were collected at 24 hours and 48 hours, pooled, and ultracentrifuged (25000 g, 4°C, 2.5 hours) to obtain concentrated lentiviruses.
用DynaBeads CD3/CD28 CTSTM(Gibco,货号40203D)激活T细胞,并在37℃和5%CO2下培养1天。然后,加入浓缩的慢病毒,持续培养3天后,获得表达包含LIR1抗体的嵌合受体的T细胞。T cells were activated with DynaBeads CD3/CD28 CTSTM (Gibco, Cat. No. 40203D) and cultured for 1 day at 37°C and 5% CO2. Then, the concentrated lentivirus was added, and after culturing for 3 days, T cells expressing the chimeric receptor containing the LIR1 antibody were obtained.
然后采用CRISPR/Cas9系统敲除野生型T细胞(即NT细胞)和所述表达包含LIR1抗体的嵌合受体的T细胞中的TCR/CD3组分(具体为TRAC基因)和MHC相关基因(具体为B2M和RFX5),分别获得Mock T细胞、LIR1-UNKi-1-T细胞(包含LIR1-1质粒)和LIR1-UNKi-2-T细胞(包含LIR1-2质粒)。并使用FITC Mouse Anti-Human CD3(BD Pharmingen,货号555916)抗体、PE mouse anti-human HLA-I(R&D货号FAB7098P)和APC anti-human DR,DP,DQ(biolegend,货号361714)抗体,通过流式细胞仪检测UNKi-T细胞、Mock T细胞和NT细胞中的CD3/HLA-I/HLA-II的表达效率,结果如下表2所示。The CRISPR/Cas9 system was then used to knock out TCR/CD3 components (specifically TRAC genes) and MHC-related genes ( Specifically, B2M and RFX5), Mock T cells, LIR1-UNKi-1-T cells (containing the LIR1-1 plasmid) and LIR1-UNKi-2-T cells (containing the LIR1-2 plasmid) were obtained, respectively. And using FITC Mouse Anti-Human CD3 (BD Pharmingen, Cat. No. 555916) antibody, PE mouse anti-human HLA-I (R&D Cat. No. FAB7098P) and APC anti-human DR, DP, DQ (biolegend, Cat. No. 361714) antibody, by flow The expression efficiency of CD3/HLA-I/HLA-II in UNKi-T cells, Mock T cells and NT cells was detected by cytometry, and the results are shown in Table 2 below.
表2.UNKi-T细胞中的基因表达效率Table 2. Gene expression efficiency in UNKi-T cells
细胞名称cell name | TCR/CD3TCR/CD3 | B2M/HLA-IB2M/HLA-I | RFX5/HLA-IIRFX5/HLA-II |
LIR1-UNKi-1-TLIR1-UNKi-1-T | 3.5%3.5% | 17.6%17.6% | 10.9%10.9% |
LIR1-UNKi-2-TLIR1-UNKi-2-T | 4.3%4.3% | 16.9%16.9% | 10.3%10.3% |
Mock TMock T | 2.6%2.6% | 15.8%15.8% | 9.3%9.3% |
NTNT | 98%98% | 98%98% | 83%83% |
从表1可以看出,本发明制备的UNKi-T细胞以及Mock T细胞中的CD3/HLA-I/HLA-II的表达被有效抑制或沉默。As can be seen from Table 1, the expression of CD3/HLA-I/HLA-II in UNKi-T cells and Mock T cells prepared by the present invention is effectively inhibited or silenced.
用recombinant human LILRB1 protein(sino biological,货号 16014-H02H)作为一抗,APC anti-human IgG Fc(biolegend,货号409306)作为二抗检测LIR1-UNKi-1 T细胞和LIR1-UNKi-2 T细胞中scFv的表达,结果如图1所示。从图1可以看出,本发明制备的UNKi-T细胞的抗LIR1 scFv均有效表达。Using recombinant human LILRB1 protein (sino biological, Cat. No. 16014-H02H) as the primary antibody and APC anti-human IgG Fc (biolegend, Cat. No. 409306) as the secondary antibody to detect LIR1-UNKi-1 T cells and LIR1-UNKi-2 T cells The expression of scFv, the results are shown in Figure 1. It can be seen from Figure 1 that the anti-LIR1 scFv of the UNKi-T cells prepared by the present invention are all effectively expressed.
用Far-Red(invitrogen,货号C34564)标记本发明制备的UNKi-T细胞和Mock-T细胞。然后按照1x10
4个细胞/孔的浓度将标记好的UNKi-T细胞和Mock T细胞铺入96孔板,并以2:1的效靶比加入NK92细胞进行共培养。16-18小时后,用流式细胞仪检测培养物中T细胞的比例,进而计算NK细胞对T细胞的杀伤率,结果如图2所示。
The UNKi-T cells and Mock-T cells prepared by the present invention were labeled with Far-Red (invitrogen, Cat. No. C34564). The labeled UNKi-T cells and Mock T cells were then plated into 96-well plates at a concentration of 1×10 4 cells/well, and NK92 cells were added at a 2:1 effector-target ratio for co-culture. After 16-18 hours, the proportion of T cells in the culture was detected by flow cytometry, and then the killing rate of NK cells to T cells was calculated. The results are shown in Figure 2.
可以看出,与Mock T相比,本实施例制备的两种表达包含LIR1抗体的嵌合受体的UNKi-T细胞均能显著降低NK细胞对T细胞的杀伤作用。It can be seen that, compared with Mock T, the two kinds of UNKi-T cells expressing the chimeric receptor containing LIR1 antibody prepared in this example can significantly reduce the killing effect of NK cells on T cells.
要说明的是,以上仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。本领域技术人员理解的是,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。It should be noted that the above are only preferred embodiments of the present invention, and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and changes. It is understood by those skilled in the art that any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.
Claims (24)
- 一种靶向LIR1的抗体,其包含:An antibody targeting LIR1 comprising:(1)如SEQ ID NO:1所示的CDR-L1、如SEQ ID NO:2所示的CDR-L2、如SEQ ID NO:3所示的CDR-L3、如SEQ ID NO:4所示的CDR-H1、如SEQ ID NO:5所示的CDR-H2、如SEQ ID NO:6所示的CDR-H3;或(1) CDR-L1 as shown in SEQ ID NO: 1, CDR-L2 as shown in SEQ ID NO: 2, CDR-L3 as shown in SEQ ID NO: 3, as shown in SEQ ID NO: 4 CDR-H1, CDR-H2 as shown in SEQ ID NO:5, CDR-H3 as shown in SEQ ID NO:6; or(2)如SEQ ID NO:10所示的CDR-L1、如SEQ ID NO:11所示的CDR-L2、如SEQ ID NO:12所示的CDR-L3、如SEQ ID NO:13所示的CDR-H1、如SEQ ID NO:14所示的CDR-H2、如SEQ ID NO:15所示的CDR-H3。(2) CDR-L1 as shown in SEQ ID NO: 10, CDR-L2 as shown in SEQ ID NO: 11, CDR-L3 as shown in SEQ ID NO: 12, as shown in SEQ ID NO: 13 CDR-H1 of SEQ ID NO: 14, CDR-H3 as shown in SEQ ID NO: 15.
- 权利要求1所述的抗体,其包含与选自SEQ ID NO:7和16所示的氨基酸序列具有至少90%同一性的轻链可变区和与选自SEQ ID NO:8和17所示的氨基酸序列具有至少90%同一性的重链可变区。The antibody of claim 1, comprising a light chain variable region having at least 90% identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 7 and 16 and a light chain variable region selected from the group consisting of SEQ ID NOs: 8 and 17 The amino acid sequence of the heavy chain variable region has at least 90% identity.
- 权利要求1所述的抗体,其中所述LIR1抗体的氨基酸序列选自SEQ ID NO:9和18。The antibody of claim 1, wherein the amino acid sequence of the LIR1 antibody is selected from the group consisting of SEQ ID NOs: 9 and 18.
- 一种核酸分子,其编码权利要求1-3任一项所述的抗体。A nucleic acid molecule encoding the antibody of any one of claims 1-3.
- 权利要求4所述的核酸分子,其与选自SEQ ID NO:19-20的核苷酸序列具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、100%序列同一性,并且其编码的LIR1抗体能够特异性结合LIR1抗原。The nucleic acid molecule of claim 4 having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% with the nucleotide sequence selected from the group consisting of SEQ ID NOs: 19-20 , 98%, 99%, 100% sequence identity, and the LIR1 antibody encoded by it can specifically bind to the LIR1 antigen.
- 一种多特异性抗体,其包含权利要求1-3任一项所述的抗体和一个或多个与其他抗原特异性结合的第二抗体或其抗原结合部分。A multispecific antibody comprising the antibody of any one of claims 1-3 and one or more secondary antibodies or antigen-binding portions thereof that specifically bind to other antigens.
- 权利要求6所述的多特异性抗体,其中所述第二抗体或其抗原结合部分选自全长抗体、Fab、Fab'、(Fab') 2、Fv、scFv、scFv-scFv、微抗体、双抗体或sdAb。 The multispecific antibody of claim 6, wherein the second antibody or antigen-binding portion thereof is selected from the group consisting of full-length antibody, Fab, Fab', (Fab') 2 , Fv, scFv, scFv-scFv, minibody, Diabodies or sdAbs.
- 一种载体,其包含编码权利要求1-3任一项所述的抗体或权利要求6或7所述的多特异性抗体的核酸分子。A vector comprising a nucleic acid molecule encoding the antibody of any one of claims 1-3 or the multispecific antibody of claim 6 or 7.
- 一种宿主细胞,其表达权利要求1-3任一项所述的抗体或权利要求6或7所述的多特异性抗体。A host cell expressing the antibody of any one of claims 1-3 or the multispecific antibody of claim 6 or 7.
- 一种嵌合受体,其包含一种或多种NK抑制性配体、跨膜结构域和信号传导结构域,其中所述NK抑制性配体包含权利要求1-3任一项所述的抗体或权利要求6或7所述的多特异性抗体,所述信号传导结构域包含一个或多个共刺激结构域。A chimeric receptor comprising one or more NK inhibitory ligands, a transmembrane domain and a signaling domain, wherein the NK inhibitory ligand comprises the NK inhibitory ligand of any one of claims 1-3 The antibody or multispecific antibody of claim 6 or 7, the signaling domain comprising one or more costimulatory domains.
- 权利要求10所述的嵌合受体,所述嵌合受体包含两种NK抑制性配体,其中第一NK抑制性配体包含权利要求1-3任一项所述的抗体或权利要求6或7所述的多特异性抗体,第二NK抑制性配体选自:(1)靶向以下NK抑制性受体的抗体或其片段:NKG2A、NKG2B、CD94、LIR2、LIR3、KIR2DL1、KIR2DL2/3、KIR3DL1、CEACAM1、LAIR1和KLRG1;和/或(2)HLA-E、HLA-F、HLA-G、钙黏素、胶原蛋白、OCIL、唾液酸、PD-L1、PD-L2、CD155、CD112、CD113、Gal-9、FGL1,和它们包含的NK抑制性受体结合区。The chimeric receptor of claim 10 comprising two NK inhibitory ligands, wherein the first NK inhibitory ligand comprises the antibody of any one of claims 1-3 or claims The multispecific antibody described in 6 or 7, the second NK inhibitory ligand is selected from: (1) an antibody or a fragment thereof targeting the following NK inhibitory receptors: NKG2A, NKG2B, CD94, LIR2, LIR3, KIR2DL1, KIR2DL2/3, KIR3DL1, CEACAM1, LAIR1, and KLRG1; and/or (2) HLA-E, HLA-F, HLA-G, cadherin, collagen, OCIL, sialic acid, PD-L1, PD-L2, CD155, CD112, CD113, Gal-9, FGL1, and the NK inhibitory receptor binding domains they contain.
- 权利要求10或11所述的嵌合受体,其中所述信号传导结构域由一个或多个共刺激结构域组成。11. The chimeric receptor of claim 10 or 11, wherein the signaling domain consists of one or more costimulatory domains.
- 权利要求10或11所述的嵌合受体,其中所述信号传导结构域还包含CD3ζ胞内区。The chimeric receptor of claim 10 or 11, wherein the signaling domain further comprises a CD3ζ intracellular domain.
- 权利要求10-13任一项所述的嵌合受体,其中所述共刺激结构域选自CD28或4-1BB胞内区。10. The chimeric receptor of any one of claims 10-13, wherein the costimulatory domain is selected from CD28 or the 4-1BB intracellular domain.
- 一种工程化免疫细胞,其表达权利要求10-14任一项所述的嵌合受体,并且其中至少一种MHC相关基因的表达被抑制或沉默。An engineered immune cell expressing the chimeric receptor of any one of claims 10-14, and wherein expression of at least one MHC-related gene is inhibited or silenced.
- 权利要求15所述的工程化免疫细胞,其中所述MHC相关基因选自:HLA-A、HLA-B、HLA-C、B2M、HLA-DPA、 HLA-DQ、HLA-DRA、TAP1、TAP2、LMP2、LMP7、RFX5、RFXAP、RFXANK、CIITA和它们的组合。The engineered immune cell of claim 15, wherein the MHC-related genes are selected from the group consisting of: HLA-A, HLA-B, HLA-C, B2M, HLA-DPA, HLA-DQ, HLA-DRA, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, CIITA, and combinations thereof.
- 权利要求15或16所述的工程化免疫细胞,其中所述工程化免疫细胞进一步包括至少一种TCR/CD3基因的表达被抑制或沉默,所述TCR/CD3基因选自TRAC、TRBC、CD3γ、CD3δ、CD3ε和CD3ζ。The engineered immune cell of claim 15 or 16, wherein the engineered immune cell further comprises suppressed or silenced expression of at least one TCR/CD3 gene selected from the group consisting of TRAC, TRBC, CD3γ, CD3δ, CD3ε and CD3ζ.
- 权利要求15-17任一项所述的工程化免疫细胞,其中所述工程化免疫细胞还表达靶向肿瘤抗原的嵌合抗原受体。The engineered immune cell of any one of claims 15-17, wherein the engineered immune cell further expresses a chimeric antigen receptor targeting a tumor antigen.
- 权利要求15-19任一项所述的工程化免疫细胞,其选自T细胞、NK细胞、NKT细胞、巨噬细胞、树突细胞。The engineered immune cell of any one of claims 15-19, which is selected from the group consisting of T cells, NK cells, NKT cells, macrophages, and dendritic cells.
- 一种抗体偶联物,其包含权利要求1-3任一项所述的抗体或权利要求6或7所述的多特异性抗体,和第二功能性结构,其中所述第二功能性结构选自Fc、放射性同位素、延长半衰期的结构部分、可检测标记物和药物。An antibody conjugate comprising the antibody of any one of claims 1-3 or the multispecific antibody of claim 6 or 7, and a second functional structure, wherein the second functional structure Selected from Fc, radioisotopes, half-life extending moieties, detectable labels and drugs.
- 权利要求20所述的抗体偶联物,其中所述延长半衰期的结构部分选自:白蛋白的结合结构、转铁蛋白的结合结构、聚乙二醇分子、重组聚乙二醇分子、人血清白蛋白、人血清白蛋白的片段和结合人血清白蛋白的白多肽;所述可检测标记物选自荧光团、化学发光化合物、生物发光化合物、酶、抗生素抗性基因和造影剂;所述药物选自细胞毒素和免疫调节剂。The antibody conjugate of claim 20, wherein the half-life-extending structural moiety is selected from the group consisting of: albumin binding structure, transferrin binding structure, polyethylene glycol molecule, recombinant polyethylene glycol molecule, human serum Albumin, fragments of human serum albumin, and human serum albumin-binding albumin polypeptides; the detectable label is selected from the group consisting of fluorophores, chemiluminescent compounds, bioluminescent compounds, enzymes, antibiotic resistance genes, and contrast agents; the The drug is selected from cytotoxic and immunomodulatory agents.
- 一种检测试剂盒,其包含权利要求1-3任一项所述的抗体、权利要求6或7所述的多特异性抗体、权利要求10-14任一项所述的嵌合受体,或权利要求20或21所述的抗体偶联物。A detection kit comprising the antibody of any one of claims 1-3, the multispecific antibody of claim 6 or 7, and the chimeric receptor of any one of claims 10-14, or the antibody conjugate of claim 20 or 21.
- 一种药物组合物,包含权利要求1-3任一项所述的抗体、权利要求6或7所述的多特异性抗体、权利要求10-14任一项所述的嵌合受体、权利要求15-19任一项所述的工程化免疫细胞或权利要求20或21所述的抗体偶联物,和一种或多种药学上可接受的赋形剂。A pharmaceutical composition comprising the antibody of any one of claims 1-3, the multispecific antibody of claim 6 or 7, the chimeric receptor of any one of claims 10-14, the The engineered immune cell of any one of claims 15-19 or the antibody conjugate of claim 20 or 21, and one or more pharmaceutically acceptable excipients.
- 权利要求1-3任一项所述的抗体、权利要求6或7所述的多特异性抗体、权利要求10-14任一项所述的嵌合受体、权利要求15-19任一项所述的工程化免疫细胞、权利要求20或21所述的抗体偶联物或权利要求23所述的药物组合物在制备用于治疗和/或预防和/或诊断与LIR1表达相关的疾病的药物中的用途。The antibody of any one of claims 1-3, the multispecific antibody of claim 6 or 7, the chimeric receptor of any one of claims 10-14, and any one of claims 15-19 The engineered immune cells, the antibody conjugates of claim 20 or 21, or the pharmaceutical composition of claim 23 are prepared for treating and/or preventing and/or diagnosing diseases associated with LIR1 expression. Use in medicine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011208654.5 | 2020-11-03 | ||
CN202011208654.5A CN114437214B (en) | 2020-11-03 | 2020-11-03 | LIR 1-targeting antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022095801A1 true WO2022095801A1 (en) | 2022-05-12 |
Family
ID=81360712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/127564 WO2022095801A1 (en) | 2020-11-03 | 2021-10-29 | Lir1-targeted antibody and use thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114437214B (en) |
WO (1) | WO2022095801A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016065329A1 (en) * | 2014-10-24 | 2016-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
CN109790213A (en) * | 2016-07-29 | 2019-05-21 | 德克萨斯大学体系董事会 | Method for identifying LILRB blocking antibody |
CN111315778A (en) * | 2017-08-23 | 2020-06-19 | 蜻蜓疗法股份有限公司 | Proteins that bind NKG2D, CD16 and tumor-associated antigens |
WO2020136145A2 (en) * | 2018-12-26 | 2020-07-02 | Innate Pharma | Leucocyte immunoglobulin-like receptor neutralizing antibodies |
CN111867614A (en) * | 2018-01-18 | 2020-10-30 | 艾达奈特公司 | anti-LILRB antibodies and uses thereof |
-
2020
- 2020-11-03 CN CN202011208654.5A patent/CN114437214B/en active Active
-
2021
- 2021-10-29 WO PCT/CN2021/127564 patent/WO2022095801A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016065329A1 (en) * | 2014-10-24 | 2016-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
CN109790213A (en) * | 2016-07-29 | 2019-05-21 | 德克萨斯大学体系董事会 | Method for identifying LILRB blocking antibody |
CN111315778A (en) * | 2017-08-23 | 2020-06-19 | 蜻蜓疗法股份有限公司 | Proteins that bind NKG2D, CD16 and tumor-associated antigens |
CN111867614A (en) * | 2018-01-18 | 2020-10-30 | 艾达奈特公司 | anti-LILRB antibodies and uses thereof |
WO2020136145A2 (en) * | 2018-12-26 | 2020-07-02 | Innate Pharma | Leucocyte immunoglobulin-like receptor neutralizing antibodies |
WO2020136147A1 (en) * | 2018-12-26 | 2020-07-02 | Innate Pharma | Compounds and methods for treatment of head and neck cancer |
Also Published As
Publication number | Publication date |
---|---|
CN114437214A (en) | 2022-05-06 |
CN114437214B (en) | 2023-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022095803A1 (en) | Cd7-targeting humanized antibody and use thereof | |
WO2021129559A1 (en) | T cell receptor fusion protein and use thereof | |
WO2022048523A1 (en) | Chimeric antigen receptor targeting nk activated receptor | |
JP2023514385A (en) | A novel chimeric antigen receptor and its use | |
WO2022089353A1 (en) | Bcma-targeting single-domain antibody and use thereof | |
WO2022152168A1 (en) | Ror1-targeting antibody and use thereof | |
EP4219693A1 (en) | Chimeric antigen receptor targeting cd7 and use thereof | |
WO2022222910A1 (en) | Gprc5d-targeting antibody and use thereof | |
US20240082306A1 (en) | Novel chimeric antigen receptor and use thereof | |
WO2021249462A1 (en) | Engineered immune cell expressing nk inhibitory molecule and use thereof | |
WO2022247795A1 (en) | Nanobody targeting claudin18.2 and use thereof | |
EP4148125A1 (en) | Engineered immune cell for allotransplantation | |
WO2022105826A1 (en) | Nkg2a-targeting antibody and use thereof | |
WO2022111405A1 (en) | Antibody targeting claudin18.2 and use thereof | |
EP4194472A1 (en) | Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof | |
WO2022095801A1 (en) | Lir1-targeted antibody and use thereof | |
CN115725503A (en) | Engineered immune cells | |
WO2022121880A1 (en) | Cd19-targeting humanized antibody and use thereof | |
WO2024001470A1 (en) | Antibody targeting b7-h3 and use thereof | |
WO2023051414A1 (en) | Mesothelin-targeting antibody and use thereof | |
CN116063527A (en) | Antibodies targeting mesothelin and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21888498 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21888498 Country of ref document: EP Kind code of ref document: A1 |